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Excitotoxicity is a pathological process involved in several 
neurodegenerative diseases such as stroke, multiple sclerosis, 
Alzheimer's disease and Parkinson's disease. Findings of a few common 
genes have suggested similar processes and mechanisms that underlie 
these diseases. However, a global and temporal profile of the gene 
expression changes in excitotoxicity has not been described extensively in 
the literature.  
 
The present study was carried out to examine global gene 
expression changes in a rat kainate (KA) injection model. KA is a widely 
used substance to induce excitotoxicity. The right hippocampus was 
harvested at 1, 14 and 28 days post-injection and analyzed by Agilent rat 
microarrays. Genes mapped to networks based on their functions and 
significance using Ingenuity Pathways Analysis (Ingenuity Systems) were 
found to be involved in Cell-mediated Immune Response, Cellular 
Movement and Immune Cell Trafficking in 1 day, whereas 14 days and 28 
days presented genes involved in Antigen Presentation, Inflammatory 
Response, Immunological Disease, consistent with other studies in 
inflammation progression.  
 
The 1 day time point presented with the highest number of genes 
with the largest upregulation, hence expression changes for genes 




by quantitative real-time polymerase chain reaction, Western blotting and 
immunohistology. Several genes were up-regulated 1 day after KA 
injection, and then gradually decreased or disappeared towards the end of 
the present study at 28 days. Several chemokines such as Ccl2 and Ccl7 
were also identified, with many being highly up-regulated at the 1 day time 
point. Immunohistology showed that some of these chemokines were 
expressed by neurons and astrocytes.  
 
Further to the findings of these highly up-regulated chemokines, 
KA-treated rats were treated with a Ccr2 antagonist to determine if acute 
or sub-acute inflammation can be reduced and to examine the impact and 
cellular activities of this effect within the inflamed brain. Treatment with the 
antagonist resulted in the slight decrease of macrophage marker Cd68 
and an increase in neuronal survival marker NeuN, suggesting 
neuroprotection. These findings not only provide molecular insight into the 
contribution of chemokines and their receptors in excitotoxic injury 
involved in stroke and neurodegenerative diseases, but also highlight the 
role of neuronal chemokines and their receptors in the injury process.
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 Neurodegeneration is an event that involves the loss of neurons 
either by programmed cell death (apoptosis) or acute or slow progressive 
cell injury. The neuron is the primary functional unit of the central nervous 
system (CNS) and has various and unique properties in functional roles 
(sensory, motor and autonomic), distribution of interconnections, 
communication by neurotransmitters, metabolic requirements and levels of 
electrical activity (Cotran et al. 1999). Neurons are also postmitotic cells 
that are unable to divide further beyond embryogenesis, therefore 
destruction of any set of neurons with specific function may result in 
severe neurological deficit.   
 
1.1 Neuroinflammation 
 Inflammation is a key host defence response to injury, tissue 
ischemia, autoimmune responses or infectious agents. The CNS responds 
to peripheral inflammatory stimuli by integrating and regulating many 
aspects of the acute phase response and exhibits many local inflammatory 
responses that appear to contribute to both acute and chronic CNS 
disease (Allan & Rothwell 2003). Acute inflammation is the immediate and 
early response that occurs at the initiation of injury. In healthy CNS tissue, 
inflammatory mediators such as adhesion molecules, cytokines produced 
by neurons, astrocytes, microglia and oligodendrocytes are expressed at 
very low or undetectable levels. However in tissue injury, they are quickly 
induced to cause diverse actions (Rothwell & Luheshi 2000). Expression 
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of inflammatory mediators is increased in experimental and clinical 
neurodegenerative diseases, and studies suggest that several of these 
factors contribute directly to neuronal injury. Studies have also shown that 
when the blood-brain barrier (BBB) is compromised, peripheral blood 
components such as polymorphonuclear leukocytes and cytokines can 
cross into the CNS (Banks et al. 1989, Siegel & Brady 2011). The CNS 
can be affected not only by inflammatory mediators produced within the 
brain, but also through the actions of mediators originating from the 
periphery (Lucas et al. 2006). Chemical mediators of inflammation can 
originate from either plasma or cells. Cell derived mediators are either 
secreted or synthesized in response to a stimulus (Cotran et al. 1999) (Fig 
1).  
Fig 1. Chemical mediators of inflammation produced by cell.  
EC, endothelial cell. Adapted from Cotran 1999 
 
 Cytokines and chemokines are produced by several cell types to 
modulate the function of other cell types. Chemokines Interleukin-1 (IL-1) 
and CCL2 have been studied intensively and implicated heavily in acute 
neurodegeneration, such as stroke and head injury (Allan & Rothwell 2003, 
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Gerard & Rollins 2001). Arachidonic acid (AA) metabolites also known as 
eicosanoids can also mediate every step of inflammation (Funk 2001). The 
synthesis of eicosanoids occurs when there is mechanical, chemical, 
physical or other stimuli to the cell, eventually leading to the production of 
phospholipase and reactive oxygen species (ROS) (Cotran et al. 1999). 
Mediators of inflammation play an important role in responding to 
inflammation; however, if excessively produced, can contribute to cellular 
damage, leading to chronic inflammation (Fig 2). Chronic inflammation is 
the result of ongoing tissue damage and removal of damaging stimulus 
followed by healing and scar formation (Stevens & Lowe 2000).If the 
damaging stimulus cannot be removed, then tissue damage and tissue 
repair cannot be resolved, and a state of chronic inflammation will persist. 
Macrophages are the main effector cell type in chronic inflammation, 
having both a phagocytic and secretory role in the immune system. They 
can secrete mediators of acute inflammation as discussed earlier, 
cytokines, growth factors as well as proteases and hydrolytic enzymes 
































Fig 2. Process of inflammation. Adapted from Stevens and Lowe 2000. 
 
1.2 Neurodegenerative Diseases 
 Neurodegenerative diseases are marked by progressive loss of 
neurons in the gray matter with secondary changes in the white matter. 
Two other distinctive characteristics of neurodegenerative diseases are 
the selective pattern of neuronal loss, where one or more groups of 
neurons are destroyed while others are left intact, and the way these 
diseases arise unpredictably with no prior inciting etiology (Cotran et al. 
1999). These diseases present themselves in different ways, either with 
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specific abnormalities or only general loss of damaged neurons. In some, 
the cerebral cortex are most prominently affect while in others, areas are 
restricted to just the subcortical regions (Girolami et al. 1999). Examples of 
neurodegenerative diseases include Alzheimer's Disease (AD), 
Parkinson's Disease (PD) and Multiple Sclerosis (MS).  
 
 In AD, there is an increasing impairment of learning and memory, 
sometimes affecting language and executive functions. The disease is 
marked by loss of neurons and synapses in the cerebral cortex and certain 
subcortical regions, including the temporal and parietal lobes, frontal 
cortex and cingulate gyrus (Wenk 2003). Amyloid plaques and 
neurofibrillary tangles are often present in the affected regions of the brain 
(Tiraboschi et al. 2004).  
  
 PD arises from the loss of dopamine-generating cells in the 
substantia nigra and the most apparent symptoms are associated with 
motor impairment (Jankovic 2008). The causes of cell death are unknown, 
however an accumulation of alpha-synuclein protein (Lewy bodies) in the 
brain have been observed in this disease (Galpern & Lang 2006).  
 
 MS is an inflammatory disease of the CNS where demyelination 
around the axons of the brain and spinal cord occurs resulting in a range 
of neurological symptoms of physical and cognitive disability (Compston & 
Coles 2002). Immunological mechanisms are important to the 
pathogenesis of this disease. Early acute episodes of MS indicate 
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infiltration of immune cells into the white matter of the CNS and the loss of 
myelin. In sites with active loss of myelin, macrophages enter the lesion 
site and phagocytose damaged myelin, accumulating lipid and forming 
foam cells (Stevens & Lowe 2000). Neuronal cell death in these diseases 
may happen for various reasons, however it has been recognised that the 
underlying mechanisms of neuronal damage have been attributed to 
























  Excitotoxicity is the pathological process by which nerve cells are 
damaged or killed by excitatory neurotransmitters such as glutamate or its 
analogs (Lipton & Rosenberg 1994). Glutamate is the main excitatory 
neurotransmitter in the brain and plays a key role in various neurological 
functions including synaptic plasticity, learning and memory, cognition, 
movement and sensation (Gasic & Hollmann 1992, McEntee & Crook 
1993). Glutamate can bind to metabotropic glutamate receptors (mGluRs) 
and ionotropic glutamate receptors (iGluRs) - AMPA (α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate), NMDA (N-Methyl-D-Aspartate) and 
kainate receptors, activating the ionotropic ligand-gated cation channels to 
allow the flow of potassium (K+), sodium (Na+) and calcium (Ca2+) ions 
(Meldrum 2000). Over-activation of GluRs due to excessive glutamate 
causes a high influx of Ca2+ into the postsynaptic cell (neuron) (Dubinsky 
1993) activating a cascade of cell degradation processes involving 
enzymes such as proteases, lipases and nitric oxide synthase, eventually 
leading to cell death (Manev et al. 1989). Stimulation of any GluRs also 
results in membrane depolarization, which indirectly activates voltage-
gated Ca2+ channels (Sucher et al. 1991). The large influx of Ca2+ through 
either channels thus contributes to glutamate-mediated neurotoxicity. In 
several pathological conditions, it is this process of excitotoxicity that 
mediates neuronal injury or death. 
 
 




2.1 Neurodegenerative Diseases Inciting Excitotoxicity 
 The role of excitotoxicity in acute neurologic diseases such as 
stroke and head trauma has been strongly supported by several 
experimental studies demonstrating increased glutamate in the 
extracellular fluid in hypoxia or ischemia and attenuation of glutamate by 
antagonists (Beal 1992b). Gene expression studies have also shown 
similar upregulation of similar genes in ischemic stroke, intracerebral 
haemorrhage, kainate-induced seizures, and insulin-induced 
hypoglycemia, further supporting the concept that excitotoxicity plays an 
important role in ischemia and is an important mechanism of brain injury 
after intracerebral haemorrhage and hypoglycemia (Tang et al. 2002). In 
chronic neurodegenerative diseases however, due to the gradual onset 
and progression of disease, a slow excitotoxic process is thought to occur 
because of a excitatory amino acid receptor abnormality or an impairment 
of energy metabolism (Beal 1992a).  
  
2.2 Models of Excitotoxicity 
 The understanding that excitotoxicity plays an important role in the 
aetiology, pathology and progression of several neurodegenerative 
diseases have prompted researchers to create models of excitotoxicity in 
the hope of developing appropriate therapies that may be of clinical benefit 
in treating such diseases. Excitotoxicity has been well established in in 
vivo and in vitro systems, after administration of excitatory amino acids 
into the nervous system (Doble 1999). Excitatory amino acids are 
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endogenous or exogenous compounds that could initiate the depolarising 
effect of glutamic acid and these include quisqualic, kainic and domoic 
acids or NMDA. In vitro models have implicated the NMDA receptor 
subtype as being the main vehicle of excitotoxic damage. In most cell 
culture models, excitotoxic effects of glutamic acid can be blocked by 
NMDA receptor antagonists (Choi 1988). In vivo studies also showed 
neuroprotection offered by NMDA receptor antagonists against 
development of ischemic damage (Simon et al. 1984). Non-NMDA 
receptors have also been proven to be responsible for neuronal death.  
 
Protection against glutamic acid-evoked neurotoxicity by 
AMPA/kainate receptor antagonists has been described in different studies   
(Rothstein et al. 1993, Colotta et al. 2012, Prehn et al. 1995). These 
molecules have sustained activity even when delivered much later than 
the excitotoxic challenge (Prehn et al. 1995). AMPA/kainate receptor 
agonists, such as kainic acid, domoic acid and quisqualic acid can 
produce excitotoxic lesions when administered directly into the brain 
(Coyle 1983). This excitotoxic activity in vivo is as potent as that of NMDA 
receptor agonists and display characteristics similar to the pathological 










3. Kainate and its receptors 
 Kainic acid (KA) (2-carboxy-4-isopropenylpyrrolidin-3-ylacetic acid), 
is isolated from a type of seaweed Digenea simplex, found in tropical and 
subtropical waters (Sun & Chen 1998) and a non-degradable analog of 
glutamate. KA is 30 times more potent than glutamate as a neurotoxin and 
can bind to both AMPA and KA receptors (KARs) in the brain (Bleakman & 
Lodge 1998), however KARs have a much higher affinity for KA (Bloss & 
Hunter 2010). KARs are non-NMDA ionotropic receptors involved in either 
excitatory neurotransmission (postsynaptic) or indirectly in inhibitory 
neurotransmission (presynaptic) by facilitating the release of GABA. In the 
postsynaptic region, kainate channels similar to AMPA receptors, alleviate 
the magnesium block in NMDARs (Lau & Tymianski 2010). The KAR 
family comprises of  five distinct subunits: GluR5, GluR6, GluR7, KA1 and 
KA2 (Bloss & Hunter 2010). The KAR subfamilies have different affinity for 
glutamate. KA1 and 2 bind glutamate with a higher affinity than GluR5–7, 
suggesting a mechanism for how KARs of varied subunit composition may 
contribute to synaptic responses depending on the amount of glutamate 
released (Bloss & Hunter 2010).  By activating KARs in the presynaptic 
cell, the amount of neurotransmitters that are released from hippocampal 
mossy fiber synapses are modulated, occuring rapidly and lasting for 
seconds (Schmitz et al. 2001). The ion channel formed by kainate 
receptors is permeable to Na+ and K+ ions and to a lesser extent, to Ca2+ 
ions. Studies have shown that activation of KA receptor can increase 
intracellular Ca2+ levels, induce mitochondrial dysfunction, produce 
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reactive oxygen species (ROS), and other biochemical events that lead to 
neuronal cell death (Sun et al. 1992, Cheng & Sun 1994, Wang et al. 2005, 
Zhang & Zhu 2011).  
 
3.1 Kainate-Induced Neurodegeneration 
 KA has been used widely to conduct studies to investigate 
mechanisms of excitotoxicity similar to some neurodegenerative diseases 
and possible pharmacological intervention under excitotoxic events. Some 
of these studies include models for ischemic damage, temporal lobe 
epilepsy, oxidative damage and multiple sclerosis (Benavides et al. 1990, 
Gluck et al. 2000, Pitt et al. 2000, Furukawa et al. 2011). Excitotoxic 
neurodegeneration inflicted by KA is also often accompanied with excess 
calcium influx, inflammation, glia activation, oxidative stress, apoptotic and 
necrotic cell death (Wang et al. 2005, Zheng et al. 2011).  
 
 There are several routes of administering KA into animal models. 
KA can be injected systematically or directly into the brain (intracerebral or 
intracerebroventricular) at specific doses to induce limbic seizures 
(Goodman 1998). KA produces excitotoxic lesions when administered 
directly into the brain in vivo (Coyle 1983). Intracerebral injection causes 
neuronal damage directly at the site of injection in an excitotoxic effect and 
at distant structures by seizure induced damage (Schwob et al. 1980). The 
distant damage is due to the synaptic release of glutamate secondary to 
KA induced seizure activity ( Ben-Ari et al. 1979, Collins & Olney 1982) 
and also appears to reflect axonal connections between the affected areas 
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at the direct site of injection and the distant areas of damage (Schwob et al. 
1980). Intracerebroventricular injection consistently and preferentially 
causes hippocampal damage localised to cornu ammonis 3 (CA3) 
pyramidal neurons (Nadler et al. 1978). A more limited and easily 
duplicated pattern of neuronal damage is also obtained through 
intracerebral or intracerebroventricular KA injection in contrast to systemic 
injection (Goodman 1998). Systemic injection of KA results in extensive 
damage in several brain regions including the pyriform cortex, amygdala, 
hippocampus, gyrus olfactorius lateralis, bulbus olfactorius and tuberculum 
olfactorium (Sperk et al. 1983). Furthermore, neurons in CA3 and CA1 
regions in the hippocampal hilus seem to be more affected whereas 
granule cells in the dentate gyrus are more resistant (Sperk et al. 1983, 
Brines et al. 1995, Sperk et al. 1985).  KA also induces apoptotic neuronal 
cell death. The influx of Ca2+ ions through the opening of Ca-AMPA/KAR 
channels in the postsynpatic terminal stimulates oxidative pathways, 
generating ROS that could lead to mitochondria dysfunction, apoptosis or 
necrotic cell death pathways (Wang et al. 2005).  
 
3.1.1 Roles of Reactive Oxidative Species and Phospholipase A2 
 Reactive astrogliosis and microgliosis are closely associated with 
neurodegenerative processes and contribute to the increase of 
proinflammatory factors and ROS. ROS such as hydrogen peroxide (H2O2) 
and superoxide radical (O2 −) are produced by some cellular oxidative 
metabolic processes involving xanthine oxidase, NAD(P)H oxidases, 
metabolism of AA and the mitochondrial respiratory chain (Muralikrishna 
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Adibhatla & Hatcher 2006). Although ROS is proposed to play important 
roles in redox signaling, oxidative stress results when the formation of 
ROS exceeds the capacity of antioxidant defense systems (Taylor & Crack 
2004). Many neurodegenerative diseases are associated with increased 
levels of ROS (Bonventre 1997), the production of which can be 
contributed by PLA2 (Muralikrishna Adibhatla & Hatcher 2006, Dennis 
1994).  
 
 PLA2s comprise a family of enzymes which act on phospholipids to 
generate free fatty acids and lysophospholipid. They hydrolize the sn-2 
acyl bond of phospholipids and release AA and lysophospholipids. AA is 
subsequently modified by cyclooxygenases into inflammatory mediators 
such as eicosanoids (Dennis 1994). PLA2 has been implicated in ischemic 
injury (Arai et al. 2001), AD (Moses et al. 2006) and MS (Cunningham et al. 
2006). Synergistically with ROS, PLA2 can cause cellular damage 
including mitochondrial membranes and alter plasma membrane activity 
and mitochondrial proteins. In addition, AA and ROS can also contribute to 
formation of lipid peroxide which degrade to reactive aldehyde products 
that bind to proteins or nucleic acids and alter their function and cause 
cellular damage (Muralikrishna Adibhatla & Hatcher 2006). PLA2 inhibitors 
have been shown to protect against neurotoxicity induced by oxidative 
stressors ( Farooqui et al. 1997, Farooqui et al. 2001, Xu et al. 2002). In 
KA-induced toxicity, PLA2 inhibitors were shown to be effective in 
inhibiting cytosolic PLA2 activity and reducing its expression after KA 
injection (Ong et al. 2003). Consequently, KA-mediated excitotoxicity can 
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be used as a model to unveil mechanisms of neurodegenerative pathways 
and to shed light on the understanding of age-related neurodegenerative 
diseases. 
 
3.1.2 Roles of Chemokines 
 One of the key components of excitotoxic neurodegeneration 
inflicted by KA is inflammation. Pro-inflammatory cytokines such as 
interleukin 1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-
α (TNF-α) are secreted by affected neurons, microglia and astrocytes (De 
Simoni et al. 2000, Rizzi et al. 2003,). One of the important downstream 
events after the upregulation of these cytokines include the expression of 
chemokines by neurons, astrocytes and microglia (Che et al. 2001, 
Kalehua et al. 2004) at the injury site.  
 
 Chemokines are small inducible cytokines that are secreted and are 
involved in trafficking of white blood cells, immunosurveillance and 
inflammation (Saunders & Tarby 1999). There are four classes in this 
family based on the number and spacing of conserved cysteine motifs in 
the NH2 terminus: CXC, CC, CX3C and C chemokines (Murphy et al. 
2000). Chemokines bind to seven transmembrane spanning receptors and 
activate heterotrimeric G-proteins and signal transduction of most of their 
receptors involve cAMP inhibition and increases of intracellular calcium 
(Biber et al. 2002). Different chemokines are also known to bind to the 
same receptor but are selective in a way that all ligands that bind to the 
same receptor are of the same class (Berkhout et al. 2003). In general, 
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chemokines assist in the attraction and chemotaxis of immune cells to 
damaged tissue in the CNS and PNS (Johnston & Butcher 2002, Babcock 
et al. 2003).  
 
 Within the CNS, the expression of chemokines are mostly induced 
by inflammatory stimuli. Most neurodegenerative diseases are reported to 
be accompanied by upregulation of chemokines including prominent ones 
like CCL2, CCL3 and CCL5 (Hesselgesser & Horuk 1999, Mennicken et al. 
1999, Gerard & Rollins 2001). In particular, CCL2 expression is described 
largely in literature. It has been associated with diseases such as ischemia 
(Che et al. 2001, Buraczynska et al. 2010, Andres et al. 2011), epilepsy 
(Manley et al. 2007, Foresti et al. 2009), MS (Mahad et al. 2006, Subileau 
et al. 2009), and AD (Galimberti et al. 2006, Sokolova et al. 2009, Correa 
et al. 2011, Westin et al. 2012). Furthermore chemokines are also believed 
to recruit leukocytes across the BBB to their target during inflammation 
(Biber et al. 2002, Ge et al. 2008).  
  
 However, besides mediating local immune responses and attracting 
leukocytes in the CNS, some chemokines may also take on a protective 
role. CXCL10 has been shown to attract activated T-lymphocytes during 
viral infections. The silencing or neutralization of CXCL10 post infection 
resulted in a significant reduction of T cell trafficking into the CNS and 
prevented efficient viral control (Liu et al. 2000, Klein et al. 2005). Others 
such as CCL5 and CXCL12 have been shown to protect hippocampal 
neurons from gp120- (HIV-1 envelope protein) or amyloid-β-peptide 
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induced neurotoxicity (Meucci et al. 1998, Watson & Fan 2005) and 
CXCL2 to protect granule cells from apoptosis (Limatola et al. 2000). 
 
 The large number of chemokines involved in the overlapping 
biological activity may indicate redundancy of this system; however, 
knockout studies of specific chemokine genes have shown that they play 
important roles in preventing pathological processes in disease models 
such as experimental autoimmune encephalitis (Biber et al. 2002). 
Furthermore, in recent years, with their possible neuromodulatory roles in 
the CNS and increased expression in various CNS diseases, chemokines 
have become therapeutic targets of interest in neuroinflammatory or 
neurodegenerative diseases.  Given the wide variety of functions that 
chemokines play in the PNS, novel discoveries and increased 
understanding of roles for chemokines in the CNS may be expected and 
better pharmacological approaches for chemokines can then be designed 
to produce selective agonist and antagonists in the future (Rostene et al. 
2007).  
 
3.2 Role of Hippocampus in Kainate-Induced Neurodegeneration 
 KA administration to rodents is frequently used to study the 
mechanisms of neurodegenerative pathways induced by excitatory 
neurotransmitter agonists (Michaelis 1998). The hippocampus is especially 
sensitive to excitatory and neurotoxic insult of KA (Suzuki et al. 1995) and 
is most affected by KA compared to other structures in the brain (Ben-Ari 
et al. 1981). The hippocampal CA3 pyramidal cells are particularly 
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sensitive to excitotoxicity induced by kainate (Malva et al. 1998) because 
the CA3 subregion of the rat is particularly rich in kainate receptors - 
specifically for GluR6, KA1 and 2 (Fig 3). mRNA expression studies show 
high levels of GluR6 and KA1 expression in DG and CA3 cells in the rat 
hippocampus. KA2 mRNA is also widely expressed throughout the brain, 
including the hippocampus, cerebellum and cerebral cortex, however, 
studies suggest a predominant postsynaptic localization for KA2 receptors 
on CA3 dendritic spines (Bahn et al. 1994). Owing to the selective 
vulnerability in hippocampal neurodegeneration that can be achieved by 
administering KA through different routes of injection neuronal damage to 
different parts of the brain, KA-induced hippocampal excitotoxicity and 
injury is a suitable model for studying neurodegenerative disorders. 
 
 
Fig 3. Hippocampal formation. CA1-4 are subfields of the hippocampus proper. 
The CA regions are filled with densely packed pyramidal cells. The major 
pathways in the hippocampus combine to form a loop. External input arise comes 
from the entorhinal cortex (EC) via the perforant pathway (pp) to the DG. Granule 
cells of the DG make connections to CA3 via mossy fibers (mf) and CA3 
connects to CA1 pyramidal cells via the Schaeffer Collateral (Sch) and 
commissural fibers from the contralateral hippocampus. CA1 pyramidal cells send 
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these three pathways is glutamate. Excitotoxicity induced by intracerebral KA 
injections usually affect CA3 region the most (red box).  
Adapted from Jorgensen et al. 1993. 




4. Microarray Analysis in Animal Models 
Gene expression changes after KA-induced excitotoxic injury have 
been previously reported in other studies. Heat shock protein 70, ras-
related protein, cytochrome P450 and platelet-activating factor 
acetylhydrolase alpha 1 subunit were induced in the rat brain after 
subcutaneous KA (Tang et al. 2002). Up-regulation of genes that have 
functions in hippocampal neuronal vulnerability and remodeling of the 
extracellular matrix in rats after intraperitoneal KA injection have also been 
demonstrated (Hunsberger et al. 2005). Another study showed significant 
changes in expression of neuropeptides, which have neuroprotective 
effects, after intraperitoneal injection of KA in rats (Wilson et al. 2005) and 
increased expression of genes related to neurodegeneration and 
astrogliosis after intraperitoneal KA-nicotine injection (Akahoshi et al. 
2007). Few studies have also been carried out to examine comprehensive 
gene expression changes after excitotoxicity across different time points. A 
recent study identified genes related to neuronal plasticity, 
neurodegeneration, and inflammation/immune-response pathways after 
subcutaneous KA injection controlled by diazepam (Sharma et al. 2009). 
In this present study, the authors attempted to study gene expression 
profiles across different time points after excitotoxicity induced by kainate 
injection. They identified genes related to neuronal plasticity, 
neurodegeneration, and inflammation / immune-response pathways such 
as TNF-alpha, CCL2 and Cox2 at different times ranging from 4 hours to 
Chapter 1   Introduction 
___________________________________________________________ 
21 
28 days. Nonetheless, the use of diazepam to control seizures could have 
led to reduction of the excitotoxic process. 




5. Hypothesis and Aim 
The present study was conducted to analyze global gene 
expression changes after KA-induced excitotoxicity, in order to 
comprehensively elucidate the mechanism of neuronal injury and possible 
drug intervention for brain injury. There were three time points 
representing acute (1 day), middle (14 days) and late (28 days) stages 
after KA-induced excitotoxicity, with emphasis on the role of chemokines in 
KA-induced injury. In the present study, KA was injected 
intracerebroventricularly and excitation that was induced was not 
suppressed by any drugs. A chemical antagonist was also used in the later 
part of the present study to determine if the antagonist could be used to 
suppress inflammation and if there were any other molecular changes 
within the CNS after excitotoxicity. The hypothesis was that the 
appropriate antagonist could remedy the inflammatory process by blocking 
the most obvious chemical modulator observed in the present study. It is 
hoped that comprehensive study of gene expression profile using KA-
induced rats may provide a clue in the search for the therapeutic targets 
for stroke as well as other excitotoxic injury conditions, and provide 
identification of potential diagnostic targets for the different stages of 
neurodegeration after excitotoxic injury, and potential therapeutic targets 
for intervention in acute and chronic neurodegenerative diseases. 
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 Temporal data of histopathological changes in the brain after KA 
exposure has been reported. After excitotoxicity, glia response and 
inflammation were observed at a very early time point to as late as 4 
months after excitotoxin administration. Within 3 hours, activation of 
resident microglia (Akiyama et al. 1994), a hallmark of neuroinflammation, 
and production of proinflammatory cytokines (Sharma et al. 2008) were 
observed. Neuronal injury was observed as early as 8 hours after KA 
administration (Covolan & Mello 2000).  
 
 Following neuronal cell loss, macrophage infiltration in the lesion 
center and astrocytic proliferation at the lesion periphery were observed 
after 3 days (Liu et al. 1996), which may facilitate remodeling of the central 
nervous system and be an advantageous mechanism to recover from an 
excitotoxic insult (Isacson & Sofroniew 1992). At 21 to 45 days after KA 
administration, significant expressions of chemokines were found 
associated with reactive astrocytes and macrophages with an absence of 
apoptotic populations, indicating a role for these chemokines in mediating 
biological effects on local microenvironmental cell populations at various 
stages after trauma (Kalehua et al. 2004).  
 
 It has been shown that glia can produce factors that mediate 
neuronal cell death after injection of excitotoxin. These include tumor 
necrosis factor alpha (TNFα) (De Bock 1998) and monocyte 




chemoattractant protein-1 (MCP-1)/CCL2 (Calvo et al. 1996). After 4 
months, a proliferation of microglia cell density and reactive astrocytes 
with dense processes were still observed to be prominent in the CA3 
region of the post KA brain (Jorgensen et al. 1993). In contrast, chronically 
activated glia may also support process sprouting within surviving neurons 
following excitotoxin-induced neuronal cell death via the production of 
various neurotrophic factors, produced by microglia and astrocytes in vitro 
(Shimojo et al. 1991) and after KA induced seizures in vivo (Van Der Wal 
et al. 1994).  
  
 These different phases of injury implicate activated glia and 
inflammatory factors as possible contributors to both neuronal death and 
regeneration and may be associated with differential expression of 
different sets of genes that are largely undefined. Thus, to better 
understand the brain injury response after KA, comprehensive and 















2. Materials and Methods 
2.1. Animals 
Twenty-four male Wistar rats were used in this part of the present 
study. Each rat weighed approximately 200 g. The animals were obtained 
from the Centre for Animal Resources, Singapore and housed in the 
vivarium of the Comparative Medicine Department, NUS. Food and water 
was provided ad libitum. The rats were randomly distributed into treatment 
and non-treatment groups and were marked for different time points. The 
rats were allowed to acclimatise to their environment for 2 days before any 
form of experiment was conducted.  
 
2.2. KA Injection 
The rats in the treatment group were anesthetized with ketamine 
(75 mg/kg) and xylazine (10 mg/kg), and placed in a stereotaxic apparatus 
(Stoelting, Wood Dale, USA). KA (Tocris, UK, 1 μl of 1 mg/ml solution) was 
injected stereotaxically into the right lateral ventricle (1.0 mm caudal to 
bregma, 1.5 mm lateral to the midline and 4.5 mm from the surface of the 
cortex) through a small craniotomy using a microlitre syringe (5 μl 
Hamilton syringe).The needle was withdrawn 5 minutes after injection of 
KA and the scalp and skin sutured. All procedures performed were 
approved by the Institutional Animal Care and Use Committee of the 
National University of Singapore in accordance with the National Advisory 
Committee for Laboratory Animal Research Guidelines.  
 





2.3. Assessment of response after KA injection 
 Increased limb movements, head bobbing and hunching of the back 
was observed within an hour of post-injection. Occasional foaming at the 
mouth was also observed. The rats were returned to the animal racks with 
access to food and water when they had completely recovered from the 
anaesthesia. Only rats that had developed response to the KA injection 
were used in the present study. 
 
2.4. RNA Extraction 
The animals were sacrificed at 1, 14 and 28 days after KA injection.  
The three time points at 1, 14 and 28 days were selected by reference to 
hippocampal histopathological changes as reported previously (Sharma et 
al. 2008, Sharma et al. 2009) and represent acute (1 day), middle and late 
phases (14 and 28 days) of neuroinflammation thus allowing the 
examination of different gene expression changes at these stages. At the 
acute time point, neuronal cell death has yet to occur as compared to the 
mid or late phase. Oxidative stress markers are also increased 
significantly in the hippocampus 4 hours or 2 days, prior to neuronal cell 
death (Wang et al. 2005) whereas 14 and 28 days are relevant for middle 
and late phase of disease. Neuronal regeneration has also been shown to 
take place in the late phase of disease, 21-45 days after KA treatment 
(Cotman & Nadler 1978). They were deeply anesthetized by 
intraperitoneal injection with ketamine and xylazine and decapitated. The 
right hippocampus was dissected manually and placed in RNAlater 




(Ambion) and snap frozen in liquid nitrogen. Total RNA was isolated from 
hippocampus using TRizol reagent (Invitrogen, CA, USA) according to the 
manufacturer's recommended protocol. The RNA was purified with the 
RNeasy Mini Kit (Qiagen, Inc., CA, USA). The purified RNA was then 
stored in a −80°C freezer for further processing. 
 
2.5. Microarray Data Collection and Analysis  
Gene expression profiles of hippocampal tissues were investigated 
using Agilent Rat Microarray (Agilent Technologies, CA, USA). Total RNA 
(10 l) were submitted to the BFIG Core facility Lab (National University of 
Singapore, Department of Paediatrics), where RNA quality was analyzed 
using an Agilent 2100 Bioanalyzer, and cRNA generated and labelled 
using the one-cycle target labeling method. cRNA generated from each 
sample was hybridized to a single array according to standard Agilent 
protocols. Data collected were exported into GeneSpring v7.3 (Agilent 
Technologies, CA, USA) software for analysis using parametric test based 
on cross gene error model (PCGEM). Unpaired t-test approach was used 
to identify differentially expressed genes (DEGs).  
 
2.6. Quantitative Real-time Analysis 
The remaining isolated RNA samples that were not used for 
microarray analysis were reverse transcribed using High-Capacity cDNA 
Reverse Transcription Kits (Applied Biosystems, CA, USA). Reaction 
conditions were 25°C for 10 min, 37°C for 120 min and 85°C for 5 s. The 
7500 Real Time PCR system was used to validate the expression changes 




of genes of interest using TaqMan® Universal PCR Master Mix and gene 
specific primers and probes as listed in Table 1. β-actin was used as an 
internal control. The real time PCR conditions were initial incubation at 
50 °C for 2 min and 95 °C for 10 min followed by 40 cycles at 95 °C for 
15 s and 60 °C for 1 min. All reactions were carried out in triplicate. The 
fold change for each gene expression in the right hippocampus was 
calculated by using the 2-CT method as described previously (Livak & 
Schmittgen 2001). The mean was calculated and possible significant 
differences analyzed using one-way ANOVA, corrected for by Bonferroni. 





















Table 1. Gene specific primers and probes 
 





CD14 molecule Cd14 NM_021744 Rn00572656_g1 
CD74 molecule, major 
histocompatibility complex, class II 
invariant chain 
Cd74 NM_013069 Rn00565062_m1 
Chemokine (C-C motif) ligand 12 Ccl12 NM_001105822 Rn01464638_m1 
Chemokine (C-C motif) ligand 2 Ccl2 NM_031530 Rn00580555_m1 
Chemokine (C-C motif) ligand 3 Ccl3 NM_013025 Rn00564660_m1 
Chemokine (C-C motif) ligand 7 Ccl7 NM_001007612 Rn01467286_m1 
Chemokine (C-C motif) receptor 2 Ccr2 NM_021866 Rn01637698_s1 
Chemokine (C-X-C motif) ligand 1 Cxcl1 NM_030845 Rn00578225_m1 
Chemokine (C-X-C motif) ligand 10 Cxcl10 NM_139089 Rn00594648_m1 
Chemokine (C-X-C motif) ligand 2 Cxcl2 NM_053647 Rn00586403_m1 
Lipocalin 2 Lcn2 NM_130741 Rn00590612_m1 
Lysyl oxidase Lox NM_017061 Rn01491829_m1 
RT1 class II, locus Bb RT1-Bb NM_001004084 Rn01429090_g1 
RT1 class II, locus Da RT1-Da NM_001008847 Rn01427980_m1 
RT1 class II, locus Db1 RT1-Db1 NM_001008884 Rn01429350_m1 
Secreted phosphoprotein 1 Spp1 NM_012881 Rn00563571_m1 
Selectin E Sele NM_138879 Rn00594072_m1 
Serine (or cysteine) peptidase 
inhibitor, clade A, member 3N SerpinA3N NM_031531 Rn00755832_mH 
Syndecan 1 Sdc1 NM_013026 Rn00564662_m1 
TIMP metallopeptidase inhibitor 1 Timp1 NM_053819 Rn00587558_m1 
 
 





2.7. Network Analysis 
Genes with p-value of p<0.05 and fold change >10 and >4 for up-
regulated and down-regulated genes respectively were considered to be 
DEGs. The highest 30 regulated genes in each time point were subjected 
to Ingenuity Pathways Analysis (IPA) (http://www.ingenuity.com; Ingenuity 
Systems, Mountain View, CA). The up- or down-regulated DEGs at the 1, 
14 and 28 days time points containing gene identifiers and corresponding 
expression values were uploaded into the IPA application. Each identifier 
mapped to its corresponding object in Ingenuity's Knowledge Base (p-
value < 0.05 or >4 (up regulated) or 10 (down regulated) fold change) was 
set to identify molecules whose expression was significantly differentially 
regulated. These molecules, called Network Eligible molecules, were 
overlaid onto a global molecular network developed from information 
contained in the Ingenuity Knowledge Base. Networks of Network Eligible 
Molecules were then algorithmically generated based on their connectivity. 
A network is a graphical representation of the molecular relationships 
between molecules. Molecules are represented as nodes, and the 
biological relationship between two nodes is represented as an edge (line). 
All edges are supported by at least one reference from the literature, from 
a textbook, or from canonical information stored in the Ingenuity 









2.8. Western Blot Analysis 
 The frozen hippocampus specimens extracted from the right side of 
the rat brain were homogenized in 3ml/g of lysis buffer containing 1x TBS, 
1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS. After 
centrifugation at 12,000 g for 30 min, the protein was collected and 
concentrations were measured using the BioRad protein assay kit (Bio-
Rad Laboratories, CA, USA). Total proteins (20 g) were resolved under 
reducing conditions in 15% SDS polyacrylamide gels and transferred to a 
polyvinylidene difluoride (PVDF) membrane (Amersham Pharmacia 
Biotech, Little Chalfont, UK). For proteins CCL2 and CCL7, Spectra 
Multicolor Low Range Protein Ladder (Thermo Scientific, IL, USA) was 
used as a marker. Nonspecific binding sites on the PVDF membrane were 
blocked by incubation with 5% non-fat milk in 0.1% Tween-20 TBS (TBST) 
for 1 h. The PVDF membranes were then incubated overnight at 4oC with 
rabbit polyclonal anti-CCL2, mouse monoclonal anti-CCL7, rabbit 
polyclonal anti-osteopontin/SPP1 (Abcam, Cambridge, UK) and goat anti-
mouse SERPINA3N (R&D Systems, MN, USA) in blocking solution. After 
washing with TBST, the membranes were incubated with horseradish 
peroxidase conjugated anti-rabbit (MCP-1 and anti-osteopontin) and anti-
mouse (MCP-3 and SERPINA3N) secondary antibody for 1 h at room 
temperature and finally washed several times. The protein was visualized 
with an enhanced chemiluminescence kit (Pierce, IL, USA) according to 
the manufacturer’s instructions. The immunoreactivity of each antibody 
was compared with that of rat -actin controls and quantified based on 




scanned images of the blots with GelPro 32 analyzer software (Media 
Cybernetics, Inc., USA). 
 
2.9. Immunohistochemistry 
 Six rats were used for this part of the present study. The rats were 
sacrificed at 1 day post-KA injection. 1 day KA rats were chosen in this 
experiment in order to observe the localization of genes responsive to 
acute inflammation. The rats were deeply anesthetized and perfused 
through the left ventricle with a solution of 4% paraformaldehyde in 0.1 M 
phosphate buffer (pH 7.4). Each brain was removed and sectioned 
coronally at 100 μm using a vibrating microtome. The sections were 
washed and incubated overnight at 4oC with goat anti-CCL2, rabbit anti-
CCL7 (Abcam), mouse anti-SERPINA3N (R&D Systems) and rabbit anti-
SPP1 (Abcam) antibody diluted to 1:200 in PBS. This was followed by 
washing and incubation for 1 h in a 1:200 dilution of biotinylated secondary 
IgG (Vector, Burlingame, CA, USA) and reacted for 1 h with an avidin-
biotinylated horseradish peroxidase complex. The reaction was visualized 
by treatment in 0.05% 3,3-diaminobenzidine tetrahydrochloride solution in 
Tris buffer containing 0.05% hydrogen peroxide for 10 min. Sections were 
mounted on gelatin-coated slides and counterstained with methyl green 











3.1. Microarray Analysis 
cDNA microarray analyses identified changes in gene expression at 
1, 14 and 28 days after KA injection. Each time point in the present study 
generated a distinct genomic response in the hippocampus. There were 
more alteration of gene changes 1 day after KA injection in comparison to 
14 and 28 days. After genes of ambiguous ontology were omitted, a total 
of 105 up and down-regulated DEGs with >10 and >4 fold change 
respectively were expressed in 1 day after KA injection. Of these, 68 and 
36 genes were up and down-regulated in 1 day respectively. A total of 45 
genes were expressed in 14 days, of which 42 and 3 genes were up and 
down-regulated respectively and a total of 18 genes were expressed in 28 
days, of which 12 and 6 genes were up and down-regulated respectively.  
 
3.1.1. Differentially expressed genes found 1 day after KA treatment 
Genes that were up-regulated with the highest fold change 
expressed at 1 day after KA injection included chemokines Ccl2 and Ccl7 
with more than 900 fold change (Table 2). Microarray data showed at least 
8 chemokines that were expressed 1 day after KA injection. Other up-
regulated DEGs included secreted phosphoprotein 1 (Spp1, >308 fold 
change), serine peptidase inhibitor (SerpinA3N, >178 fold change and 
Serpine1, >122 fold change) and lectin (Lgals3, >74 fold change). The 
most down-regulated gene was hairy and enhancer of split 5 (Drosophila) 
(Hes5, >15 fold change).  





Table 2. Differentially expressed genes in the right hippocampus 1 day after 
kainate injection. These are genes that show up regulation by more than 10 folds 
and down regulation by more than 4 folds, compared to untreated rats.  
 
Gene Gene symbol 
Fold 
Change P-value 
Chemokine (C-C motif) ligand 2 Ccl2 982.87 0.00004
Chemokine (C-C motif) ligand 7 Ccl7 933.15 0.00005
Secreted phosphoprotein 1 Spp1 308.23 0.00014
Thyrotropin releasing hormone Trh* 245.87 0.00000
Serine (or cysteine) peptidase inhibitor, clade A, 
member 3N  SerpinA3N 178.19 0.00000
Fos-like antigen 1  Fosl1 173.27 0.00011
serine (or cysteine) peptidase inhibitor, clade E, 
member 1 Serpine1* 122.12 0.00029
H19, imprinted maternally expressed transcript H19 79.86 0.00046
chemokine (C-X-C motif) ligand 1 Cxcl1 77.70 0.00018
lectin, galactoside-binding, soluble, 3 Lgals3 74.22 0.00009
heat shock protein 1  Hspb1 64.17 0.00002
G protein-coupled receptor, family C, group 5, member 
A Gprc5a 59.43 0.00108
TIMP metallopeptidase inhibitor 1 Timp1 58.49 0.00005
CD14 molecule Cd14 44.53 0.00068
Tubulin, beta 6 Tubb6 41.83 0.00008
Chemokine (C-C motif) ligand 3 Ccl3 40.76 0.00013
Syndecan 1 (Sdc1) Sdc1* 37.62 0.00057
Lipocalin 2 Lcn2 37.41 0.00026
Calcitonin-related polypeptide alpha (Calca), transcript 
variant 1 Calca* 37.24 0.00058
Chemokine (C-X-C motif) ligand 10 Cxcl10 36.42 0.00075
Lysyl oxidase Lox* 35.55 0.00001
Asparaginase homolog (S. cerevisiae) Aspg 34.51 0.00003
P-selectin Precursor  Selp 32.78 0.00126
Rattus norvegicus family with sequence similarity 167, 
member A  Fam167a 30.24 0.00039
Selectin E  Sele 26.88 0.00085
Sphingosine kinase 1 Sphk1 23.91 0.00011
B-cell CLL/lymphoma 3 Bcl3 23.77 0.00032
Heat shock protein 3 Hspb3 23.54 0.00009
Protein C receptor, endothelial Procr 22.33 0.00394
Heat shock 70kD protein 1B Hspa1b 19.94 0.00001
Tumor necrosis factor receptor superfamily, member 
12a Tnfrsf12a 19.84 0.00033
Secretory leukocyte peptidase inhibitor Slpi 19.24 0.01040
Activating transcription factor 3 Atf3 19.15 0.00044
Chemokine (C-C motif) ligand 12 Ccl12 18.65 0.00044
Chemokine (C-X-C motif) ligand 2 Cxcl2 18.54 0.00245
Plasminogen activator, urokinase receptor (Plaur), 
Transcript variant 1 Plaur 17.90 0.00129




Gliomedin (Gldn) Gldn 17.15 0.00177
Glycoprotein (transmembrane) nmb Gpnmb 15.09 0.00042
Inhibin beta-A (Inhba) Inhba 14.54 0.00214









    
Gene Gene symbol 
Fold 
Change P-value 
Hexokinase 3, nuclear gene encoding mitochondrial 
protein Hk3 14.23 0.00246
Interleukin 1 receptor antagonist Il1rn 13.74 0.01367
1-acylglycerol-3-phosphate O-acyltransferase 2 Agpat2 12.94 0.00037
Follistatin-related protein 3 Precursor Fstl3 12.87 0.00169
Heme oxygenase (decycling) 1 Hmox1 12.71 0.00043
Potassium intermediate/small conductance calcium-
activated channel Kcnn4 12.70 0.00088
Serine (or cysteine) peptidase inhibitor, clade B, 
member 2 Serpinb2 12.36 0.00729
Placenta-specific 8 Plac8 12.04 0.00150
Coagulation factor II F2 12.00 0.00011
Lectin, galactoside-binding, soluble, 4 Lgals4 11.96 0.00054
C-type lectin domain family 12, member A  Clec12a 11.89 0.00032
Neutrophil cytosolic factor 4 Ncf4 11.38 0.00019
Pentraxin related gene Ptx3 11.34 0.00087
Vimentin Vim 11.00 0.00015
Oxidized low density lipoprotein (lectin-like) receptor 1 Olr1 11.00 0.00165
Integrin, alpha 5  Itga5 10.93 0.00583
Receptor-interacting serine-threonine kinase 3 Ripk3 10.83 0.00031
Cardiotrophin-like cytokine factor 1 Clcf1 10.82 0.00093
Epithelial membrane protein 1 Emp1 10.69 0.00055
Heparin-binding EGF-like growth factor Hbegf 10.62 0.00150
GLI pathogenesis-related 1 Glipr1 10.36 0.00088
Suppressor of cytokine signaling 3 Socs3 10.31 0.00238
Mitogen-activated protein kinase kinase kinase 6 Map3k6 10.25 0.00076
Relaxin 3 Rln3 10.14 0.00417
Peripheral myelin protein 2 Pmp2 10.13 0.00321
SLAM family member 9 Slamf9 10.02 0.00508
Unc-13 homolog C Unc13c -4.01 0.00232
Ephrin B3 Efnb3 -4.02 0.00030
Aldehyde oxidase 1 Aox1 -4.05 0.00272
Adenylate cyclase 1 Adcy1 -4.09 0.00097
Neurotrophin 3 Ntf3 -4.34 0.00046
FK506 binding protein 6 Fkbp6 -4.37 0.00436
Solute carrier family 22 (organic anion transporter), 
member 8 Slc22a8 -4.38 0.01460
hedgehog acyltransferase-like Hhatl -4.46 0.00075
Fin bud initiation factor homolog (zebrafish) Fibin -4.48 0.01608
Apoptosis-inducing factor, mitochondrion-associated 3 Aifm3 -4.56 0.00615
Acyl-CoA synthetase medium-chain family member 5 Acsm5 -4.56 0.04422
Tubulin tyrosine ligase-like family, member 9 Ttll9 -4.61 0.00134
Na+/K+ transporting ATPase interacting 4 Nkain4 -4.66 0.00075
Claudin 10 Cldn10 -4.66 0.00277
C-ros oncogene 1 , receptor tyrosine kinase Ros1 -4.69 0.00015
Cytochrome P450, family 4, subfamily f, polypeptide 4 Cyp4f4 -4.72 0.00091
Membrane metallo endopeptidase Mme -4.93 0.00321
Growth differentiation factor 10 Gdf10 -5.18 0.00911
Phosphorylase kinase, gamma 1 Phkg1 -5.18 0.00174
Histamine N-methyltransferase Hnmt -5.20 0.00151
Selenium binding protein 1 Selenb1 -5.34 0.00300
Potassium channel tetramerisation domain containing 4 Kctd4 -5.40 0.00009
BTB (POZ) domain containing 17 Btbd17 -5.43 0.00400








Granzyme M (lymphocyte met-ase 1) Gzmm -5.90 0.00001
Adrenergic, beta-3-, receptor Adrb3 -6.24 0.00045




    
Gene Gene symbol 
Fold 
Change P-value 
Camello-like 5 Cml5 -6.25 0.00122
Nescient helix loop helix 1 Nhlh1 -6.32 0.00004
Peptidase domain containing associated with muscle 
regeneration 1 Pamr1 -7.03 0.00672
Dopa decarboxylase Ddc -7.16 0.00730
5-hydroxytryptamine Htr5b* -7.23 0.00014
Nephroblastoma overexpressed gene Nov* -7.59 0.00063
Serine dehydratase Sds* -7.94 0.00934
Probable N-acetyltransferase (Camello-like protein 3)  Cml3* -11.76 0.00122
Polo-like kinase 5 Plk5 -13.17 0.00000
Hairy and enhancer of split 5 (Drosophila) Hes5* -15.62 0.00429
* Up regulated genes found uniquely in 1 day 
 
3.1.2. Differentially expressed genes found 14 days after KA 
treatment 
Genes that were up-regulated more than 10 folds at 14 days after 
KA injection included Spp1 (>129 fold change), followed by Cd74 (>90 fold 
change) and MHC/RT1 class II Bb (>66.6 fold change), Da (>65 fold 
change) and Db1 (>51.8 fold change). There were 3 DEGs with known 
ontology that were down-regulated at 14 days after KA injection. These 
were Solute carrier (Slc28a2, >6.9 fold change), RT1 class (RT1-M6-1, 
>4.3 fold change) and vomeronasal 2 receptor (Vom2r52, >4.2 fold 














Table 3. Differentially expressed genes in the right hippocampus 14 days 
after kainate injection. These are genes that show up regulation by more than 
10 folds and down regulation by more than 4 folds, compared to untreated rats. 
 
Gene Gene symbol 
Fold 
Change P-value 
Secreted phosphoprotein 1  Spp1 129.33 0.0001 
Cd74 molecule, major histocompatibility complex, 
class II invariant chain Cd74 90.88 0.0004 
RT1 class II, locus Bb  RT1-Bb 66.67 0.0004 
RT1 class II, locus Da RT1-Da 65.08 0.0016 
RT1 class II, locus Db1  RT1-Db1* 51.83 0.0019 
Chemokine (C-C motif) ligand 3 Ccl3 36.79 0.0009 
G protein-coupled receptor 183 Gpr183 31.17 0.0007 
Potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 4 (Kcnn4) Kcnn4 27.50 0.0016 
Oxidized low density lipoprotein (lectin-like) receptor 1 Olr1 25.05 0.0014 
Lectin, galactoside-binding, soluble, 3  Lgals3 23.10 0.0007 
GLI pathogenesis-related 1  Glipr1 21.43 0.0013 
T-cell immunoglobulin and mucin domain containing 2 Timd2* 20.12 0.0013 
G protein-coupled receptor 18  Gpr18 19.70 0.0017 
Cd68 molecule Cd68 19.14 0.0012 
RT1 class Ia, locus A2 RT1-A2 19.13 0.0349 
C-type lectin domain family 12, member A  Clec12a 18.95 0.0014 
sodium channel, voltage-gated, type VII, alpha Scn7a 18.86 0.0008 
chemokine (C-C motif) ligand 2 Ccl2 16.59 0.0194 
chemokine (C-C motif) ligand 7 Ccl7 16.15 0.0158 
Fc fragment of IgG, low affinity IIb, receptor (CD32) Fcgr2b 15.89 0.0009 
chemokine (C-X-C motif) ligand 17 Cxcl17 14.99 0.0042 
complement component 3  C3 14.78 0.0011 
asparaginase homolog (S. cerevisiae) Aspg 14.68 0.0015 
glycoprotein (transmembrane) nmb  Gpnmb 14.58 0.0025 
 RT1 class I, locus CE10  RT1-CE10 14.35 0.0038 
protein tyrosine phosphatase, receptor type, C 
(Ptprc), transcript variant 4 Ptprc 14.33 0.0008 
Z-DNA-binding protein 1  Zbp1 14.11 0.0092 
suppression of tumorigenicity 14 (colon carcinoma) St14 13.99 0.0029 
C-type lectin domain family 7, member a  Clec7a 13.70 0.0037 
integrin, beta 2 (Itgb2) Itgb2 13.62 0.0022 
RT1 class I, locus CE5  RT1-CE5 13.02 0.0026 
ADP-ribosylation factor-like 11 Arl11 13.01 0.0010 
DENN/MADD domain containing 2D Dennd2d 12.11 0.0025 
neutrophil cytosolic factor 1 Ncf1 12.08 0.0024 
S100 calcium-binding protein A4 S100a4 11.90 0.0006 
CD86 molecule Cd86 11.80 0.0018 
vanin 1 (Vnn1) Vnn1* 11.13 0.0007 
protein tyrosine phosphatase, non-receptor type 7  Ptpn7 10.62 0.0024 
serine (or cysteine) peptidase inhibitor, clade G, 
member 1  Serping1 10.44 0.0026 
vomeronasal 2 receptor, 52 Vom2r52 -4.29 0.03453 
RT1 class I, locus M6, gene 1  RT1-M6-1 -4.32 0.00441 
solute carrier family 28 (sodium-coupled nucleoside 
transporter), member 2 Slc28a2 -6.99 0.00944 
* Up regulated genes found uniquely in 14 days    
 





3.1.3. Differentially expressed genes found 28 days after KA 
treatment 
Many of the genes up-regulated at 28 days were similar to those 
found at 14 days (Table 4). Spp1 (>56.4 fold change) was the highest up-
regulated gene, followed by Cd74 (>39.5 fold change), RT1 class II Db1 
(>31.9 fold change), Bb (30.1 fold change) and Da (27.7 fold change). 
Down-regulated genes included cystic fibrosis transmembrane 
conductance regulator homolog (Cftr, >9.1 fold change), solute carrier 
family 28, member 2 (Slc28a2, >6.7 fold change) and neuronal PAS 
domain protein 4 (Npas4, >5.7 fold change). 
 
Table 4. Differentially expressed genes in the right hippocampus 28 days 
after kainate injection. These are genes that show up regulation by more than 
10 folds and down regulation by more than 4 folds, compared to untreated rats. 
 
Gene Gene symbol 
Fold 
Change P-value 
Secreted phosphoprotein 1  Spp1 56.45 0.0110 
Cd74 molecule, major histocompatibility complex, 
class II invariant chain Cd74 39.48 0.0097 
RT1 class II, locus Db1 RT1-Db1 31.92 0.0136 
RT1 class II, locus Bb RT1-Bb 30.11 0.0128 
RT1 class II, locus Da RT1-Da 27.73 0.0259 
G protein-coupled receptor 183 Gpr183 19.60 0.0066 
RT1 class Ia, locus A2 RT1-A2 15.53 0.0429 
Sodium channel, voltage-gated, type VII, alpha Scn7a 13.58 0.0171 
Lectin, galactoside-binding, soluble, 3 Lgals3 13.41 0.0109 
C-type lectin domain family 12, member A Clec12a 12.43 0.0147 
Chemokine (C-C motif) ligand 3 Ccl3 12.20 0.0171 
Asparaginase homolog (S. cerevisiae)  Aspg 11.28 0.0079 
Cystic fibrosis transmembrane conductance regulator 
homolog Cftr -9.14 0.0112 
Solute carrier family 28, member 2 Slc28a2 -6.74 0.0024 
Neuronal PAS domain protein 4  Npas4 -5.77 0.0151 
Leukocyte immunoglobulin-like receptor, subfamily B 
(with TM and ITIM domains), member 3-like (Lilrb3l) Lilrb3l -5.21 0.0059 
Solute carrier family 27 (fatty acid transporter), 
member 2 Slc27a2 -4.14 0.0440 
Vomeronasal 2 receptor, 52 Vom2r52 -4.07 0.0401 
 





3.1.4. Differentially expressed genes exclusive to 1, 14 or 28 days 
after KA treatment 
Genes with more than 2 fold change were compared across all 3 
time points and exclusive genes for each time point were identified. A total 
of 1735 genes were found expressed exclusively at 1 day after KA 
injection in contrast to untreated controls, of which 909 (52.4%) were up-
regulated and 826 (47.6%) were down-regulated. There were 347 DEGs 
identified at 14 days after KA injection - 324 (93.4%) were up-regulated 
and 23 (6.6%) down-regulated. At the 28 days time point, there were 167 
DEGs expressed exclusively, of which 67 (40.1%) were up-regulated and 
100 (59.9%) were down-regulated. The top 5 DEGs for each time point are 


















Table 5. Differentially expressed genes in the right hippocampus found 
exclusively in 1, 14 and 28 days after kainate injection. These are top 5 genes 
that show up and down regulation compared to untreated rats, foldchange >2 
 





Thyrotropin releasing hormone Trh 245.87 0.0000 
Serine (or cysteine) peptidase inhibitor, 
clade E, member 1 Serpine1 122.12 0.0003 
Syndecan 1 Sdc1 37.62 0.0006 
Calcitonin-related polypeptide alpha Calca 37.24 0.0006 
Lysyl oxidase Lox 35.55 0.0000 
Hairy and enhancer of split 5 (Drosophila) Hes5 -15.62 0.0043 
Probable N-acetyltransferase CML3 (EC 
2.3.1.-)(Camello-like protein 3) Cml3 -11.76 0.0012 
Serine dehydratase Sds -7.94 0.0093 
Nephroblastoma overexpressed gene Nov -7.59 0.0006 
5-hydroxytryptamine (serotonin) receptor 
5B 
1 day 
Htr5b -7.23 0.0001 
     
T-cell immunoglobulin and mucin domain 
containing 2  Timd2 20.12 0.0013 
Vanin 1 Vnn1 11.13 0.0007 
Protein tyrosine phosphatase, receptor 
type, C-associated protein Ptprcap 9.69 0.0044 
Lymphocyte-activation gene 3 Lag3 7.83 0.0013 
Synaptotagmin X Syt10 -2.57 0.0162 
Cortistatin Cort -2.39 0.0026 
HRAS-like suppressor  Hrasls -2.33 0.0127 
Elongation of very long chain fatty acids Elovl3 -2.19 0.0385 
Early growth response 4 
14 days 
Egr4 -2.17 0.0112 
     
Keratin 18 Krt18 3.97 0.0365 
Radial spokehead-like 3 Rshl3 3.58 0.0122 
Macrophage stimulating 1 Mst1 3.51 0.0479 
Forkhead box J1 Foxj1 3.04 0.0013 
Sarcoglycan, gamma Sgcg 2.97 0.0261 
Neuronal PAS domain protein 4 Npas4 -5.77 0.0151 
Leukocyte immunoglobulin-like receptor, 
subfamily B Lilrb3l -5.21 0.0059 
Arachidonate 15-lipoxygenase Alox15 -3.67 0.0002 
Erythroid associated factor Eraf -3.14 0.0039 
Ribosomal protein L28 
28 days 












3.1.5. Differentially expressed genes exclusive to 1 day after KA 
treatment 
The up-regulated genes that appeared exclusively at the 1 day time 
point after KA injection included thyrotropin releasing hormone (Trh, 
>245.8 fold change), Serpine1 (>122.2 fold change), syndecan 1 (Sdc1, 
>37.6 fold change), calcitonin-related polypeptide (Calca, >37.2 fold 
change) and lysyl oxidase (Lox, >35.5 fold change). Down-regulated 
genes that were expressed only at the 1 day timepoint included Hes5, 
camello-like protein (Cml3, >11.7 fold change) and serine dehydratase 
(Sds, >7.9 fold change).   
 
3.1.6. Differentially expressed genes exclusive to 14 days after KA 
treatment 
The up-regulated genes that were expressed uniquely at 14 days 
after KA injection included T-cell immunoglobulin and mucin domain 
containing 2 (Timd2, >20.2 fold change), vanin 1 (Vnn1, >11.1 fold 
change), and protein tyrosine phosphatase, receptor type, C-associated 
protein (Ptprcap >9.6 fold change) while down-regulated genes included 











3.1.7. Differentially expressed genes exclusive to 28 days after KA 
treatment 
The up-regulated genes that were expressed only at 28 days after 
KA injection included keratin (Krt18, >3.9 fold change), radial spokehead-
like (Rshl3, >3.5 fold change), macrophage stimulating 1 (Mst1, >3.5 fold 
change), forkhead box (Foxj1, >3 fold change) and sarcoglycan (Sgcg, 
>2.9 fold change). Down-regulated genes included neuronal PAS (Npas4, 
>5.7 fold change), arachidonate 15-lipoxygenase (Alox15, >3.6 fold 
change) and ribosomal protein L28 (Rpl28, >3.1 fold change).  
 
3.1.8. Differentially expressed genes common to all time points 
Genes in common across all time points were also identified. These 
genes that were up-regulated at each time point were also altered at two 
other time points representing 5% of all differentially expressed genes (Fig 
4). The most up-regulated genes in common include Spp1, Ccl7, Cd74, 




























Fig 4. Venn diagram from microarray analysis indicating the number of 
genes expressed at 1, 14 and 28 days after KA injection. The 1 day time point 
had the most number of regulated genes while the 28 days had the least. There 














Table 6. Differentially expressed genes in the right hippocampus found in common in 1, 14 and 28 days after kainate injection. These 
are top 5 genes that show up- and down-regulation compared to untreated rats, foldchange >2 
 
 1 Day 14 Days 28 Days 







Secreted phosphoprotein 1 Spp1 308.23 0.0001 129.33 0.0001 56.45 0.0110 
Chemokine (C-C motif) ligand 7 Ccl7 933.15 0.0000 16.15 0.0158 5.41 0.0383 
Cd74 molecule, major histocompatibility complex, class II invariant chain Cd74 7.69 0.0020 90.88 0.0004 39.48 0.0097 
Lectin, galactoside-binding, soluble, 3 Lgals3 74.22 0.0001 23.10 0.0007 13.41 0.0109 
RT1 class II, locus Bb RT1-Bb 7.47 0.0054 66.67 0.0004 30.11 0.0128 
Rattus norvegicus polo-like kinase 5 Plk5 -13.17 0.0000 -2.24 0.0301 -2.59 0.0047 
Rattus norvegicus androgen regulated 20 kDa protein Andpro -3.42 0.0253 -3.16 0.0352 -3.41 0.0234 
Rattus norvegicus dickkopf homolog 4 (Xenopus laevis) Dkk4 -3.31 0.0359 -2.98 0.0492 -3.53 0.0342 
Rattus norvegicus SH3 domain binding glutamic acid-rich protein like 2 Sh3bgrl2 -2.77 0.0007 -2.42 0.0020 -3.87 0.0023 
Rattus norvegicus FXYD domain-containing ion transport regulator 7 Fxyd7 -3.74 0.0002 -2.66 0.0124 -2.70 0.0384 






3.2. Network analyses 
Genes with significant changes in expression following KA injection 
were assigned to different pathways and subjected to IPA where the 
resulting top 30 DEGS at 1, 14 and 28 days after KA injection were 
mapped to networks defined by the IPA database.  
 
3.2.1. Networks in 1 day  
IPA mapped a total of 6 and 4 networks in up- and down-regulated 
DEGs with >10 and >4 fold change respectively from the 1 day time point. 
The largest network from up-regulated DEGs had 14 focus molecules from 
the micoarray dataset. The DEGs in this network are Bcl3, Ccl3l3, Ccl7, 
Cxcl10, Cxcl2, Cd14, Lcn2, Msr1, Sdc1, Sele, Selp, SerpinA3N, Spp1 and 
Timp1. These are involved in cellular movement, hematological system 
development and function and immune cell trafficking (Fig 5). The second 
network generated had 10 focus molecules and included genes Calcb, 
Ccl2, Fosl1, H19, Lgals3, Lox, Procr, Serpine1, Sphk1 and Trh. These had 
functions in Cellular Movement, Gene Expression, Cell Death. The largest 
network generated by down-regulated DEGs is involved in cellular growth 
and proliferation, cancer and neurological disease. Molecules in this 
network include Hes5, Nov, Sds and Cml5. 
 
 






Fig 5. Network of genes mapped in 1 day after KA injection. The genes in this 
network are involved in Cell-mediated Immune Response, Cellular Movement, 
Immune Cell Trafficking. NFB and chemokine were centered in this network. 










3.2.2. Networks in 14 days  
Five networks from up-regulated DEGs were mapped while 2 
networks were mapped from down-regulated genes. The largest network 
had 14 focus molecules and included Ccl2, Ccl3, Ccl7, Cxcl17, Cd68, 
Cd74, Fcgr2b, RT1-A2, Bb, Da, Db1, Lgals3, Olr1 and Spp1. These are 
involved in cell-to-cell signaling and interaction, hematological system 
development and function, and immune cell trafficking (Fig 6). The network 
generated from down-regulated genes involved only MHC and RT1-M6-
1/2 and these are involved in cell mediated immune response, cellular 
















Fig 6. Network of genes mapped in 14 days after KA injection. The genes are 
involved in Antigen Presentation, Inflammatory Response, Immunological 
Disease. RT1 genes were distinctive in this network. Grey nodes  are genes 
derived from the microarray analysis.  
 
3.2.3 Networks in 28 days  
There were 3 networks mapped from up-regulated DEGs and 2 
networks from down-regulated DEGs at the 28 days time point. The 
largest network from up-regulated DEGs is involved in cell death, cell-to-





cell signaling and interaction, hematological system development and 
function (Fig 7). Genes involved include Ccl3l3, Lgals3, Spp1, Gpr183, 
Cd74 and RT1-A1, Db1, Da, Bb. The largest network made up of down-
regulated DEGs include ion channel Cftr and transporters Slc27a2 and 
Slc28a2. These are involved in cell morphology, reproductive system 
development and function, and respiratory disease. 
 
Fig 7. Network of genes mapped from 28 days after KA injection. The genes 
are involved in Antigen Presentation, Inflammatory Response, Genetic Disorder. 
The RT1 genes were the main molecules in this network. Grey nodes  are genes 
derived from the microarray analysis. 






3.3. mRNA expression levels of differentially expressed genes after 
KA injection 
Real-time RT-PCR was used to validate the results of the 
microarray analysis of highly expressed chemokines Ccl2, Ccl7, Cxcl1, 
Ccl3, Cxcl10, Ccl12 and Cxcl2 and genes Spp1, SerpinA3N, Timp1, Cd14, 
Sdc1, Lcn2, Lox and Sele at the 1 day time point. Many of these also 
appeared in the largest network of up-regulated DEGs at 1 day after KA 
injection. Genes Cd74, RT1-Db1, RT1-Da and RT1-Bb that had higher 
expression at the 14 and 28 days time point were also verified. Cxcl2, 
Ccr2, Ccl3, Spp1 and Lox were up-regulated significantly at 1 day 
compared to control, but Ccl3 and Spp1 were also significantly decreased 
at 14 and 28 days; Lox was significantly decreased at 28 days compared 
to 1 day. SerpinA3N, Lcn2, Ccl7 were significantly increased at 1 and 14 
days compared to control and decreased significantly at 14 and 28 days 
compared to 1 day. Ccl12 was significantly increased at 1 and 14 days 
compared to control but decreased significantly at 28 days compared to 1 
day. Timp1, Cxcl10, Cxcl1, Ccl2, Sele, Sdc and Cd14 were significantly 
up-regulated at 1 day compared to control and were decreased at 14 and 
28 days compared to 1 day (Fig 8A-B). RT1-Da, Bb and Cd74 were 
significantly up-regulated at 14 and 28 days compared to control. In 
addition, Cd74 was also increased significantly at 14 days compared to 1 
day. RT1-Db1 was significant at 14 days compared to control (Fig 8C).  
 
 



























Fig 8A. Expression of the highest regulated genes expressed after KA 
injection (fold change > 500). The genes were verified by RT-PCR and are 
distributed into 2 scales; The upper scale show the fold changes of Ccl2 (>1600), 
SerpinA3N (>1500), Ccl7 (>700) and Spp1 (>200) after 1 day KA injection while 
the lower scale show the fold changes for control, 14 and 28 days after KA 
injection. All the genes were significant p<0.002 at 1 day compared to control, 
marked with a single asterisk. SerpinA3N, Ccl7, Spp1 and Ccl12 also showed 
significance at 14 days compared to control (p<0.05, not indicated). Double 
asterisks indicate significance between 1 day and 14 days (p<0.002) and triple 
asterisks indicate significance between 1 day and 28 days (p<0.05). There was 







































Fig 8B. Expression of the highest regulated genes expressed after KA 
injection (fold change <100). All the genes were significant at 1 day compared 
to control (single asterisk, p< 0.05). Lcn2 and Ccl3 were significant between 14 
days and control (not indicated, p<0.005). Double asterisks indicate significance 









Fig 8C. Expression of the highest regulated genes expressed after KA 
injection (14 and 28 days time point). These genes were the most highly 
expressed at the 14 and 28 days time point. All the genes were significant at 14 
days compared to control (single asterisk, p< 0.05). Double asterisks indicate 
significance between 28 days and control (p< 0.05) and triple asterisks indicate 
significance between 1 day and 14 days (p< 0.05). There was no significance 












3.4. Protein expression levels of differentially expressed genes after 
KA injection 
 Data from RT-PCR verified the mRNA expression of several highly 
expressed genes at various time points. The 1 day time point after KA 
injection presented DEGs with the highest regulation therefore Western 
blotting was performed to determine protein levels of the top few highest 
expressing DEGs. A band at approximately 14kDa for CCL2 from 1 day 
KA hippocampus homogenate was detected, consistent with the expected 
molecular weight of CCL2. A larger band at approximately 25kDa was also 
detected possibly due to post translational modification (O-glycosylation) 
(Jiang et al. 1990, UniProt 2012) (Fig 9A). The osteopontin antibody 
recognised the 32kDa MMP-cleaved C-fragment (Fig 9B). Extensive 
phosphorylation on clustered serine residues have been identified for this 
protein (Keykhosravani et al. 2005). A single band at approximately 59kDa 
was detected for SERPINA3N (Fig 9C), consistent with the expected 












































Fig 9. Protein Expression after 1 day KA injection. Western blot analysis of 
(A) CCL2, (B) SPP1 and (C) SERPINA3N in the right hippocampus after 1 day 
KA injection. Immunoblot staining for β-actin is shown as a control for protein 
loading. (D) The graph shows densitometric analysis of the protein levels after 
normalization by the β-actin protein level. The data was analysed by Student’s t-
test, asterisks indicate significant difference (*p < 0.05, **p < 0.01) and are 
expressed as mean ± SEM, n = 3 per treatment group.  
 


























































 Extensive cell death was observed in KA-treated rat hippocampus 
in Nissl stained sections (not shown). Light immunostaining for Ccl2 was 
observed in sections from control rats. Control sections incubated with 
antigen absorbed antibody showed absence of labeling (Fig. 10A). 
Increased Ccl2 labeling was observed in neurons of the CA1 and CA3 
region and in the dentate gyrus (Fig 10B-D). A similar pattern of 
immunostaining was observed for Ccl7. Light immunostaining for Ccl7 was 
observed in sections from control rats. The sections incubated with antigen 
absorbed antibody showed no staining for astrocytes (Fig 11A). In contrast, 
sections from rats that had been injected with KA showed increased 
immunoreactivity to Ccl7 in neuronal cells in the CA1 and CA3 field after 1 
day KA-injection. In CA1, the labelled cells had processes characteristic of 
astrocytes (Fig 11B-D). Light immunostaining for SerpinA3N was observed 
in sections from control rats in CA1 and dentate gyrus (fig 12A-B). In 
sections from 1 day KA-injected rats, increased immunolabelling was 
observed in neurons of the CA1 region and dentate gyrus (Fig 12C-D). 
Light immunostaining for Spp1 was observed in sections from control rats. 
Sections incubated with antigen absorbed antibody showed absence of 
labelling in the dentate gyrus (Fig 13A) whereas there was increased 
immunolabelling observed in the dentate gyrus in 1 day KA-injected rats 
(Fig 13B).  
 
 















Fig 10. Ccl2 upregulation in hippocampal region 1 day after KA injection. 
Light micrographs of (A) right hippocampal section in 1 day control rat. Increased 
Ccl2 staining observed in (B) CA1, (C) CA3 and (D) dentate gyrus in 1 day KA-












Fig 11. Ccl7 upregulation in hippocampal region 1 day after KA injection. 
Light micrographs of (A) right hippocampal section in 1 day control rat. Increased 
Ccl7 staining observed in (B) CA1 and (C) CA3 in 1 day KA-injected rats. Ccl7 
labelled cells of 1 day rat section had characteristics of astrocytes in (D) CA1 































Fig 12. SerpinA3N upregulation in hippocampal region 1 day after KA 
injection. Light micrographs of right hippocampal sections of (A) CA1 and (B) 
dentate gyrus in 1 day control rats. Neurons in (C) CA1 and (D) dentate gyrus 
had increased labelling for SerpinA3N in 1 day KA-injected rats. Scale: 100µm for 






Fig 13. Spp1 upregulation in hippocampal region 1 day after KA injection. 
Light micrographs of right hippocampal sections of (A) dentate gyrus in 1 day 
control rats. Neurons in (B) dentate gyrus were heavily labelled for Spp1 in 1 day 

















A comprehensive gene expression study was conducted to 
evaluate gene changes in the hippocampus after KA-induced excitotoxicity. 
Results showed that several genes that were up-regulated at 1 day after 
KA injection are involved in cell movement, migration, recruitment, 
accumulation and activation of neutrophils, leukocytes, phagocytes, 
granulocytes, macrophages, lymphocytes, antigen presenting cells and 
dendritic cells. The findings support previous studies reporting the genes 
involved in neurodegeneration (Sharma et al. 2009) and highlight the 
importance of inflammatory response at the early phase of excitotoxic 
brain injury. There was an upregulation of several genes encoding 
chemokines at 1 day after KA injection and these were further validated by 
RT-PCR.  
 
 Chemokines play an important role in neuroinflammation, mediating 
local immune responses and attracting leukocytes that may migrate across 
the blood brain barrier to their target. They display chemotactic activity for 
leukocytes in many CNS diseases such as brain trauma (Glabinski et al. 
1996), ischemic brain injury (Kim et al. 1995, Minami & Satoh 2003) and 
Alzheimer’s disease (AD) (Sokolova et al. 2009). mRNA levels of Ccl2 was 
found to be especially high at 1667 fold. Ccl2 is one of the few but 
prominent chemokine frequently described in the injured CNS (Biber et al. 
2002) and is not only expressed by glia cells, but also by neurons in 
neuronal degeneration (Schreiber et al. 2001, Che et al. 2001). In the 





central nervous system (CNS), astrocytes (Dorf et al. 2000), 
oligodendrocytes (Nguyen & Stangel 2001), microglia (Boddeke et al. 
1999) and neurons (Coughlan et al. 2000) have been shown to express 
functional chemokine receptors, synthesize distinct chemokines and 
respond to stimulation by chemokine receptor expression (Hesselgesser & 
Horuk 1999, Asensio & Campbell 1999, Mennicken et al. 1999). Ccl2 is 
expressed in several brain regions, including the hippocampus and is 
involved in chemoattraction, neurogenesis, orienting cell migration, 
differentiation or neuromodulators (Rostene et al. 2007, Zhou et al. 2011, 
Toyomitsu et al. 2012).  
 
Closely related to Ccl2 is Ccl7, the third most up-regulated gene 
observed in the 1 day KA time point at more than 700 fold. Ccl7 attracts 
several types of leukocytes including lymphocytes, granulocytes, NK cells, 
and dendritic cells (Thompson & Van Eldik 2009). Ccl7 specifically attracts 
monocytes and regulates macrophage function. A study demonstrated that 
stimulated astrocytes produce numerous chemokines specific for 
monocytes/macrophages and may play a major role in enhancing 
monocyte recruitment initiated by Ccl7 (Renner et al. 2011). 
Immunohistochemistry results in this study show the expression of Ccl7 in 
astrocytes, consistent with previous studies of Ccl7 expression in 
astrocytes in multiple sclerosis (Szczucinski & Losy 2007), neuroAIDS 
(Renner et al. 2011) and ischemic stroke (Wang et al. 1999).  
 
 





The results also indicate that a diverse set of genes increased in 
response to the acute KA treatment. SerpinA3N (alpha-1-antichymotrypsin, 
ACT) had the second largest fold change in mRNA expression 1 day after 
KA injection. There was an increase in SerpinA3N mRNA expression at 1 
day which gradually decreased at the end of 28 days. SerpinA3N is a 
protease inhibitor whose protein is produced in the liver and is an acute 
phase protein which is produced during acute (Kalsheker 1996) and 
chronic (Licastro et al. 2000) inflammation. SerpinA3N is from a large 
family of functionally diverse proteins - serine protease inhibitors. Most 
inhibitors are involved in intra- or extracellular processes such as blood 
clotting, cell migration, proliferation, complement activation and tumour 
suppression (Forsyth et al. 2003). 
 
SerpinA3N is often associated with AD, where mRNA of SerpinA3N 
is overexpressed in AD grey matter but is not highly expressed in normal 
brain conditions (Abraham et al. 1988). However, the present study has 
shown that SerpinA3N may also be expressed in the brain under other 
neuroinflammatory conditions. Besides SerpinA3N, microarray results 
show that expression of other serpins such as SerpinA11, B1 (Monocyte 
neutrophil elastase inhibitor), B2 (Plasminogen activator inhibitor-2), F1 
(Pigment epithelium derived factor), F2 (Alpha 2-antiplasmin), G1 
(Complement 1-inhibitor), H1 (47 kDa Heat shock protein), E1 
(Plasminogen activator inhibitor 1) and I1 (neuroserpin) may be altered at 
1 day after KA injection. These results suggest that altered expression of 





serpins may accelerate the brain damage at the early stage of 
excitotoxicity. 
 
Secreted phosphoprotein 1 (Spp1 also known as osteopontin) was 
observed to be one of the most highly up-regulated gene 1 day after KA 
injection. Spp1 is a highly phosphorylated sialoprotein that is a prominent 
component of the mineralized extracellular matrices of bones and teeth 
and has been implicated as an important factor in bone remodeling (Choi 
et al. 2008). Spp1 is induced in macrophages and microglia in the region 
around a stroke, with subsequent up-regulation of its integrin receptor on 
astrocytes (Wang et al. 1998, Ellison et al. 1999). More recently, Spp1 was 
proposed to act as an opsonin that facilitates phagocytosis of neuronal 
debris by macrophages in the ischemic brain (Shin et al. 2012). 
Suggestions have been made to indicate that calcium precipitation 
provided a matrix for the binding of the Spp1 protein within the debris or 
degenerating neurites induced by ischemic injury and may participate in 
the regulation of ectopic calcification in the ischemic brain (Shin et al. 
2012). Spp1 also induces the expression of proinflammatory cytokines and 
chemokines including Ccl2 that play important roles in promoting migration 
of cells (Xu et al. 2005).  
 
Other genes that were highly regulated at 1 day after KA injection 
included Timp-1, CD14 and Lcn2. Timp-1 is a member of the matrix 
metalloproteinases (MMPs) family important in regulation of cell-cell 
interaction and preservation of extracellular matrix (ECM) structure, by 





inhibiting MMP-2 and MMP-9. ECM degradation has been observed in 
several physiopathological conditions, including metastasis and 
inflammatory processes (Murphy & Nagase 2008). It may also be involved 
in atherosclerotic lesions (Silence et al. 2002). Cd14 is a component of the 
innate immune system up-regulated by microglia cells and uptakes 
bacterial component lipopolysaccharide (LPS) via macropinocytosis 
(Poussin et al. 1998, Vasselon et al. 1999). CD14 has been shown to 
mediate phagocytosis of bacterial components (Muro et al. 1997, Peterson 
et al. 1995), apoptotic events (Devitt et al. 1998) and contribute to 
neuroinflammation in Alzheimer's disease (Balistreri et al. 2008, Landreth 
& Reed-Geaghan 2009, Reed-Geaghan et al. 2010, Rodriguez-Rodriguez 
et al. 2008). It may also play a role in clearance of atherogenic lipoproteins 
(Schmitz & Orso 2002). Lcn2 is strongly up-regulated during inflammation 
and is up-regulated by interleukin 1 (but not TNF alpha) in humans 
(Cowland & Borregaard 1997). Lcn2 expression is strongly induced in 
astrocytes, neurons, and neutrophils after contusion injury (Rathore et al. 
2011). Single and double immunostaining confirmed that LCN2 is present 
in selected brain regions such as astrocytes in the olfactory bulb, 
brainstem and cerebellum of the normal brain, and reactive astrocytes in 
the KA-lesioned hippocampus (Chia et al. 2011).  
 
 At the 14 days time point, a decrease in expression of chemokines 
was observed, especially Ccl2 and Ccl7 to 11 and 12 folds respectively in 
large contrast to the 1 day time point. Instead upregulation in expression of 
major histocompatibility complex (MHC or RT in rats) was observed. The 





14 days KA-injected rats presented with 4 class II (Cd74, locus Bb, Da, 
Db1) and 3 class I RT1 types (locus A2, locus CE10, CE5). MHC class I 
(MHCI) is expressed by all nucleated cells while MHC class II (MHCII) 
normally occurs only on antigen presenting cells, macrophages, B cells 
and dendritic cells. MHCI molecules present antigen to cytotoxic T-cells 
while MHCII molecules present antigen to helper T-cells. The MHCII 
molecules are from the transmembrane receptor family and are regulated 
by many genes including TNF, dendritic cells and IFN (Chu & Lowell 
2005, Schattenberg et al. 2000, Carbonneil et al. 2004, Tan & O'Neill 2005, 
Le Bon & Tough 2002). T-cells (CD4) that recognise MHCII molecules 
activate other effector cells in the immune system, hence class II 
molecules are normally expressed by B lymphocytes, dendritic cells and 
macrophages (Janeway 2001).  
 
 MHCI may be found at low levels in the neurons of healthy CNS 
(Corriveau et al. 1998); however, MHCI and II may be up-regulated at this 
stage as a line of disease defence, as they are displayed by antigen 
presenting cells to T-cells which elicit a cascade of response to eliminate 
foreign pathogen (Janeway 2001). Interestingly, studies have shown that 
pro-inflammatory cytokines such as interferon-γ (IFN-γ) and tumor 
necrosis factor-α (TNF-α) can induce expression of MHCI (Neumann et al. 
1997). Thus because of the high levels of pro-inflammatory factors in the 
CNS in the present study, this may explain for why dysregulation of 
otherwise normal MHCI expression might occur. Furthermore, activated 
microglia, which were observed to be increased in the 





immunohistochemical study, can increase upregulation of MHCI and II 
expression, facilitating their role in immune mediated events, allowing 
microglia to interact with T cells (Stoll et al. 2002, John et al. 2003). 
 
At the 28 days time point, there were 12 DEGs, of which 5 were 
RT1 class I or II genes. At this point where most genes had lower 
expression, Spp1 remained high at 56 fold, suggesting extended 
regulation in the CNS during inflammation. Cd74 was the second most up-
regulated gene after Spp1 in the microarray and qPCR analysis. Cd74 is 
involved in antigen presentation, often found in macrophages, B-cells and 
dendritic cells (Bijlmakers et al. 1994, Karlsson et al. 1994, Brown et al. 
1993) which are vital in the adaptive immune system during an 
inflammatory process. Besides its primary role in antigen presentation, 
studies have also shown Cd74 as a receptor complex for macrophage 
migration inhibitory factor (MIF), (Leng et al. 2003, Jorgensen et al. 2010), 
a cytokine-like molecule that mediates both innate and adaptive immunity 
and is involved in chronic inflammation (Beswick & Reyes 2009).  
 
The top 30 genes from each time point generated various networks 
according to their functions and association with Network 1 containing the 
most number of differentially expressed genes. In agreement with the 
microarray and qPCR results reported above, Network 1 from the 1 day 
KA time point was built around the chemokines and involved in cell-
mediated immune response, cellular movement and immune cell 
trafficking. View of the largest network generated from the 1 day KA 





injection time point also identified NF-ĸB as a key regulatory signal 
molecule that is affected by KA treatment. This is consistent with the 
results of a number of previous studies which have demonstrated 
increased activation of NF-κB in the hippocampus and other brain regions 
after KA treatment (Matsuoka et al. 1999, Rong & Baudry 1996, Won et al. 
1999, Nakai et al. 2000, Cruise et al. 2000, Lubin et al. 2005, Ridder & 
Schwaninger 2009). NF-ĸB has been also reported to regulate chemokine 
expression (Richmond 2002, Barnes & Karin 1997, Genin et al. 2000, 
Moriuchi et al. 1997) and be involved in the inflammatory signaling 
mechanism (Ridder & Schwaninger 2009, Burke et al. 2012). Together, 
these findings suggest that the altered NF-κB activity after KA injection 
causes increased transcription of chemokines. 
 
In Network 1 of the 14 days KA time point, Ccl2 and NF-κB appear 
similarly centered in the network as seen in the 1 day KA network. 
However, the 14 day network mapped fewer chemokines that were seen 
highly expressed at 1 day, instead including expression of more MHC 
(RT1) molecules. Ccl3 or macrophage inflammatory protein 1 alpha (MIP-
1a) was also mapped in the same network at the 14 days KA time point. 
Ccl3 is a chemoattractant for monocytes and T cells and is studied widely 
in relation to HIV as they are known to compete for the same receptor 
(Cocchi et al. 1995). The present qPCR results showed that Ccl3 was not 
as highly up-regulated in the 1 day time point compared to Ccl2 and Ccl7 
but was increased in the 14 day time point through to 28 days, with 
expression still remaining higher than that of other chemokines, which had 





normalised by 28 days. The time course pattern observed was similar to a 
previous study on temporal gene expression of Ccl3 in SE rats. Ccl3 was 
highly up-regulated at 1 day and 4 days after SE stimuli but gradually 
resolved by 30 days (Guzik-Kornacka et al. 2011). The present data, as 
evidenced by the previous study, indicates that Ccl3 mRNA expression, 
unlike other chemokines, remains increased in the brain for longer periods 
of time after neuroinflammation; however, the role of prolonged Ccl3 
expression in the brain is not yet known. 
 
Network 1 in the 28 days time point included 9 genes in association 
with antigen presentation, inflammatory response, and genetic disorder. 
The network largely involved the MHC molecules (RTI classes), as well as 
Ccl3, Spp1 and Lgals3. There was sustained expression of antigen 
presentation cells such as MHC Class II genes, which were also seen at 
the 14 day time point whereas other genes such as the chemokines 
(excepting Ccl3) that were seen up-regulated at 1 and 14 days were 
completely normalised at 28 days. Galectin-3 (Lgals3) is a 30 kDa β-
galactosidase-binding lectin, that binds IgE and glycoconjugates on 
mammalian cell surfaces. It can expressed in epidermal cells of various 
organs, dendritic cell and various inflammatory cells such as macrophages 
and microglia. Lgals3 expression is increased by inflammation and cell 
differentiation plays a role in cell proliferation and apoptotic regulation (Liu 
et al. 2002). It has been reported that galectin-3 is expressed by resident 
microglia cells in experimental models of adult stroke (Walther et al. 
2000) and (Yan et al. 2009). 






The findings of the present study are generally consistent with the 
results of previous studies that focused on identifying specific altered 
genes after neuronal injury in a temporal fashion (Manley et al. 2007, 
Sharma et al. 2009). Clinical studies on chemokine expression in humans 
with neuroinflammatory conditions also support the present findings in the 
KA rat model. Gene expression studies on hippocampal specimen from 
temporal lobe epilepsy patients identified upregulation of chemokines, 
indicating that they may directly or indirectly affect neuronal excitability 
(van Gassen et al. 2008). Similar to some of the present findings, a clinical 
study showed significant expression of CCL2, MMP-9, TIMP-1, IL6, CRP 
and brain damage marker S100B in the blood of patients with transient 
ischemic attack or ischemic stroke after symptom onset. While the levels 
of IL-6, CCL2 and MMP-9 increased within a few hours after symptom 
onset, CRP and S100B gradually rose commencing at 12-24 h and TIMP-
1 demonstrated an extended plateau (Worthmann et al. 2010). Similarities 
in changes in expression of genes in both animal and clinical studies help 
to validate a common pathway during excitotoxic brain injury. 
 
 The striking increased expression of mRNA encoding chemokines, 
especially Ccl2 (>1667 fold, p<0.00003) and Ccl7 (>741 fold, p<0.00001) 
in rat hippocampus at 1 day after KA treatment was presented at levels not 
observed before. It has been suggested that stimulus of any form that 
changes cellular homeostasis can lead to expression of inducible 
chemokines, resulting in an increase of mRNA encoding induced 





chemokines of 300-fold within a few hours of activation (Gerard & Rollins 
2001), however, the sensitive induction and high expression may result in 
persistent expression of chemokines. Damage caused by activated 
leukocytes may not be able to suppress the chemokine stimulus that  
initiated their recruitment, leading to higher expression of these or even 
new chemokines and resulting in more extensive tissue damage (Gerard & 
Rollins 2001).  
 
The data also showed the upregulation of Ccr2 (>11 fold, p<0.01) at 
the 1 day time point. Ccr2 is a receptor for all four human MCP 
chemokines (MCP1-4) (Gong et al. 1997, Wain et al. 2002). Both Ccl2 and 
Ccl7 bind to Ccr2 to stimulate efficient migration of macrophages and 
monocytes across brain macrovasculature (Seguin et al. 2003, Mahad et 
al. 2006). The functional importance of this receptor has been defined in 
several systems, including immune trafficking (Bruhl et al. 2004) and 
allograft rejection (Abdi et al. 2004), by the application of specific receptor 






































 Ccr2 is expressed on monocytes, activated memory T cells, B cells, 
and basophils in humans (Nomiyama et al. 2001) and recognizes the 
ligands Ccl2/Mcp-1, Ccl8/Mcp-2, Ccl7/Mcp-3, and Ccl13/Mcp-4 (Berkhout 
et al. 2003). Many studies have shown that Ccl2 and its receptor Ccr2 play 
important roles in various neurodegenerative diseases. The expression of 
Ccl2 is increased in many diseases such as ischemia, which are marked 
by inflammation and inflltrating monocytes (Mennicken et al. 1999). The 
importance of Ccl2 in monocyte trafficking has been demonstrated through 
Ccl2 and Ccr2 knockout mice. In these studies, the loss of Ccl2 or Ccr2 
function was sufficient to impair recruitment and trafficking of inflammatory 
cells ( Hughes et al. 2002, Mahad et al. 2006, Schuette-Nuetgen et al. 
2012). As such inhibition of Ccl2 binding to its receptor would prevent the 
migration of monocytes into the affected tissue and suppress inflammation, 
thus inhibition would be expected to be beneficial for patients suffering 
from certain diseases (Xia & Sui 2009). 
 
 In the past years, drug discovery of small molecule antagonists of 
chemokine receptors have been developed and advanced upon (Trivedi et 
al. 2000). Four chemically distinct types of antagonists have been 
developed against Ccrs - these include SB-282241, TAK-779, lead 
compound from Teijin and RS-504393 (Berkhout et al. 2003). RS-504393 
is a specific compound that targets Ccr2 as an antagonist (Fig 14). This 
molecule is neither a chemotaxis agonist nor does it stimulate postreceptor 




signaling of any kind. The compound specifically inhibits Ccl2 and Ccl7 
signaling through Ccr2 and is not an antagonist of Cxcr1, Ccr1, or Ccr3 







Fig 14. Ccr2 antagonist RS-504393 
 
 Owing to the large success of clinical proof of concept of Ccr5 
antagonists, Ccr2 has become the next most studied receptor as a drug 
target after Ccr5. As a result of the importance of Ccr2 in monocyte 
trafficking, the clinical potential of Ccr2 antagonists is wide, ranging from a 
variety of inflammatory diseases and pain. In vitro studies have shown 
successes in the use of Ccr2 antagonist and a few of which have 
progressed into clinical trials. Although clinical trials have yet to achieve 
complete success in the treatment of certain diseases, efforts to further 
improve Ccr2 antagonists in inflammatory diseases have not decreased. 
Recent positive outcomes of clinical trials of the Ccr2 antibody MLN-1202 
in MS and atherosclerosis may be the best evidence of clinical proof of 
concept for Ccr2 as a therapeutic target so far. In this chapter, the 
possibilities of using RS-504393 in reducing inflammation induced by 
excitotoxicity in the brain were explored. 





2. Materials and Methods 
2.1. Animals 
Twenty male Wistar rats of approximately 200 g each were used in 
this part of the study. The animals were obtained from the Centre for 
Animal Resources, Singapore and housed in the vivarium of the 
Comparative Medicine Department, NUS. Food and water was provided 
ad libitum. The rats were allowed to acclimatise to their environment for 2 
days before any form of experiment was conducted.  
 
2.2. Ccr2 Intervention 
  Rats were anesthetized with ketamine (75 mg/kg) and xylazine (10 
mg/kg), and injected with KA (Tocris, UK, 1 μl of 1 mg/ml solution) as 
described in the method from the earlier chapter. Only rats that had 
developed the expected response to KA injection were used in the present 
study. The rats were returned to the rack stand with free access to food 
and water after they had recovered from the anaesthesia.  
 
Twelve KA-treated rats were fed orally twice daily with a CCR2 
antagonist, RS-504393 (1mg in vehicle consisting of 50 % DMSO in 
saline) or vehicle alone. A total of 2 mg/kg of RS-504393 or vehicle was 
fed to each rat per day on days four and five after KA or saline-injection. 
The dosage was selected based on reference to a study where CCR2 
antagonist RS-504393 decreased Ccl2 expression and macrophage 
infiltration in kidney ischemia-reperfusion injury in mice compared to 




control, suggesting a key role for Ccl2 via CCR2 signaling (Furuichi et al. 
2003). Eight sham operated rats received intracerebroventricular injection 
of saline and served as controls. These were similarly fed with CCR2 
antagonist RS-504393 or vehicle. The rats were gavaged orally using a 
curved stainless steel needle with a ball tip. After 7 days, the rats were 
deeply anesthetized by intraperitoneal injection of ketamine/xylazine 
cocktail (0.2 ml/100 g) and decapitated. 
 
2.3. RNA Extraction 
The hippocampus from the right brain was dissected manually and 
placed in RNAlater (Ambion) and snap frozen in liquid nitrogen. Total RNA 
was isolated from the hippocampus using TRizol reagent (Invitrogen, CA, 
USA) according to the manufacturer's recommended protocol. The RNA 
was purified with the RNeasy Mini Kit (Qiagen, Inc., CA, USA). The 
purified RNA was then stored in a −80°C freezer for further processing. 
 
2.4 Quantitative RT-PCR 
Isolated RNA samples were reverse transcribed using High-
Capacity cDNA Reverse Transcription Kits (Applied Biosystems, CA, USA). 
Reaction conditions were 25°C for 10 min, 37°C for 120 min and 85°C for 
5 s. The 7500 Real Time PCR system was used to validate the expression 
changes of Ccl2, Ccl7, SerpinA3N, Cd68 and NeuN using TaqMan® 
Universal PCR Master Mix and gene specific primers and probes. β-actin 
was used as an internal control. The real time PCR conditions were initial 
incubation at 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles at 




95 °C for 15 s and 60 °C for 1 min. All reactions were carried out in 
triplicate. The fold change for each gene expression in the right 
hippocampus was calculated by using the 2-CT method as described 
previously (Livak & Schmittgen 2001). The mean was calculated and 
possible significant differences analyzed using one-way ANOVA, corrected 
for by Bonferroni. Values with p < 0.05 were considered significant. 
 
2.5. Western Blot Analysis 
 The frozen hippocampus specimen from the right brain were 
homogenized in 3ml/g of lysis buffer containing 1x TBS, 1% Nonidet P-40, 
0.5% sodium deoxycholate, and 0.1% SDS. After centrifugation at 12,000 
g for 30 min, the protein was collected and concentrations were measured 
using the BioRad protein assay kit (Bio-Rad Laboratories, CA, USA). Total 
proteins (20 g) were resolved under reducing conditions in 15% SDS 
polyacrylamide gels and transferred to a polyvinylidene difluoride (PVDF) 
membrane (Amersham Pharmacia Biotech, Little Chalfont, UK).  
Nonspecific binding sites on the PVDF membrane were blocked by 
incubation with 5% non-fat milk in 0.1% Tween-20 TBS (TBST) for 1 h. 
The PVDF membrane was then incubated overnight at 4oC with mouse 
monoclonal Cd68 (Santa Cruz, Ca, USA) and anti-NeuN (Millipore) in 
blocking solution. After washing with TBST, the membrane was incubated 
with horseradish peroxidase conjugated anti-mouse and anti-goat for 1 h 
at room temperature and finally washed several times. The protein was 
visualized with an enhanced chemiluminescence kit (Pierce, IL, USA) 
according to the manufacturer’s instructions. The immunoreactivity of each 




antibody was compared with that of rat -actin controls and quantified 
based on scanned images of the blots with GelPro 32 analyzer software 
(Media Cybernetics, Inc., USA). 
 
3. Results 
3.1 mRNA expression of Ccl2 after CCR2 antagonist treatment 
Treatment of KA rats with RS-504393 resulted in no significant 
changes of Ccl2, Ccl7 and SerpinA3N compared to vehicle fed KA group 
however there was a significant increase in Ccl2, Ccl7 and SerpinA3N in 
the KA group compared to the sham group. This increase was expected 
due to the effects of KA injection (Fig 15A). mRNA levels of neuronal and 
macrophage markers (NeuN and Cd68) were also determined. Cd68 was 
not significantly down-regulated after RS-504393 treatment compared to 
vehicle treatment in the KA-injected group. There was also no difference 
observed in the sham group. In contrast, NeuN showed significant up-
regulation after RS-504393 treatment compared to vehicle in the KA-
injected group, P<0.0005 (Fig 15B). 
 
3.2 Protein expression of markers after CCR2 antagonist treatment 
 Protein levels of CD68 and NEUN were determined by Western 
blotting. CD68 produced a band at 35 kDa. There was no difference 
observed for CD68; however, 2 bands for NEUN at 46 and 48 kDA 
showed significant upregulation after RS-504393 treatment compared to 
vehicle treatment in the KA-injected group, p<0.05 (Fig 16). 
 
















































Fig 15. mRNA expression of Ccl2, Ccl7, SerpinA3N and markers after RS-
504393 treatment. RT-PCR was used to determine the mRNA levels in (A) Ccl2, 
Ccl7, and SerpinA3N after RS-504393 treatment. After RS-504393 treatment (B) 
Cd68, macrophage marker was slightly but not significantly down-regulated 
whereas NeuN, neuronal marker was significantly up-regulated compared to the 













































































































































Fig 16. Protein expression of CD68 and NEUN after RS-504393 treatment. 
Protein expression of (A) CD68 was not significant for RS-504393 treated rat in 
both KA- and sham-injected rats in comparison to vehicle. NEUN showed no 
difference between treatment of RS-504393 and vehicle in the sham group, 
however there was significant upregulation in the RS-504393 treated rats 
compared to the vehicle treated rats in the KA group. (B) Densitometry of protein 
analysis, p<0.05 (asterisk). SH=Sham injected (saline); KA=Kainate injected; 
V=Vehicle (DMSO); I=Inhibitor (RS-504393). 
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Inflammation and inflammatory mediators such as chemokines or 
prostaglandins may have dual roles, with detrimental acute effects but 
beneficial effects in long-term repair and recovery (Lucas et al. 2006). In a 
study of ischemic stroke, administration of a Ccr2 antagonist in conjunction 
with angiotensin II receptor antagonists decreased ischemic brain area 
after middle cerebral artery occlusion (Tsukuda et al. 2011). On the 
contrary, studies have also shown that blocking Ccr2 may have negative 
effects, especially if Ccl2 appears to be protective. Ccl2 knock-out mice 
presented a decrease in cortical neuronal cell density in comparison with 
wild-type animals suggesting that the presence of Ccl2 is required for 
normal neuronal development or survival (Godefroy et al. 2012).  
 
Ccr2 is the receptor for Ccl2 and Ccl7. In the hippocampus of 
normal and pilocarpine-induced SE rats, the majority of Ccr2-expressing 
cells are neurons (Foresti et al. 2009). Excess Ccl2 may thus over 
facilitate excitatory neurotransmission in neurons through CCR2 receptor, 
which could further contribute to excitotoxicity. Gene deficient and 
knockdown animals showed a role of this receptor system in ischemic 
stroke via facilitating leukocyte infiltration and inflammatory mediator 
expression (Hughes et al. 2002, Dimitrijevic et al. 2007, Dimitrijevic et al. 
2006, Yan et al. 2007). The microarray and RT-PCR results in the present 
study showed that Ccl2 and Ccl7 were still up-regulated 7 days after KA-
injection, and we sought to elucidate possible effects of blocking the 




receptor of Ccl2 and Ccl7 with Ccr2 antagonist RS-504393, on several 
genes involved in chemokines and macrophage infiltration, and neuronal 
survival.  
 
The data in the present study showed that RS-504393 did not 
significantly block Ccl2 receptor; possibly due to an insufficient dosage 
administered to the rats however it prevented neuronal loss in response to 
KA, when administered on days 4 and 5 after KA treatment. This was 
demonstrated via the upregulation of NeuN, whose immunoreactivity is 
obvious as neurons mature. It was also shown that downstream response 
in the inflammatory cascade was altered or reduced. This finding is the 
first to show that the administration of Ccr2 antagonist via a clinically-
relevant, oral administration route and delayed time window has a 
neuroprotective effect in a rat excitotoxicity model. Moreover, the 
protective results do not seem to be primarily dependent on inhibition of 
migration of macrophages, since Cd68 levels were not significantly 
decreased by the Ccr2 antagonist. The results suggest that neuronal Ccr2 
play an important role in neuronal cell death after excitotoxicity, and point 
to the possible use of Ccr2 antagonists as a neuroprotective agent in 
acute neurological diseases. 
 
Several clinical trials are in progress for the use of Ccr2 in diseases 
where there could be an excitotoxic component. Interestingly, many of 
these are slow progressing diseases, where there may be ongoing slow 
excitotoxicity. These include studies in MS (Xia & Sui 2009, Horuk 2009). 




Therefore, the blocking of Ccr2 after the onset of events appears to still 
have beneficial effects in the CNS. The potential of Ccr2 needs to be 
further verified as it will help in future development of clinical diagnostic 
biomarkers and therapeutic targets for neurological diseases involving 
excitotoxicity, and address the differential gene expression pattern and 
temporal profile of such expression in damaged tissues. 


































 Many excitotoxicity studies to date have been focused on either 
disease specific or mediator specific outcome. Gene expression in 
temporal studies on early and late stage inflammation have also not been 
described in great details, thereby making the question for common 
mechanisms for different CNS diseases and potential targets more 
complicated. The present study was conducted to provide a global view on 
excitotoxicity, a common underlying mechanism in many neurological 
diseases such as stroke, AD or head injury. In some diseases such as PD 
or MS, excitotoxicity may play a secondary role. Here, gene expression 
levels are reported and described when insult and injury are inflicted, 
followed by inflammation in early and late stages in the CNS.  
 
 The microarray data verified by RT-PCR revealed a large number of 
pro-inflammatory mediators such as Ccl2 and Ccl7; however a high 
upregulation after 1 day was unexpected. Other temporal studies using KA 
have reported the largest number of genes up-regulated at 14 days after 
KA administration compared to 3 days (Sharma et al. 2009). The present 
study has shown that as early as 1 day, gene expression changes have 
already begun to make significant regulation. Furthermore, activation and 
recruitment of glia cells, a common event associated with neuronal injury 
was present in the hippocampus 1 day after KA injury. Both astrocytes and 
microglia cells become activated under pathological conditions and 
contribute to the increase of pro-inflammatory factors like cytokines 




(Hanisch 2002). The mechanism associated with increased expression of 
chemokines (Ccl2 and Ccl7) in KA-mediated hippocampal injury is 
currently unclear. However, it is suggested that oxidative stress in KA-
mediated neurotoxicity activates NF-κB, which after its translocation to the 
nucleus may trigger the expression of Ccl2 and Ccl7 not only in non-neural 
cells, such as mononuclear phagocytes, but also in neurons (Farooqui AA 
et al. 2008). High levels of chemokines may also trigger sufficient vascular 
permeability to induce seizures and facilitate demise of hippocampal 
neurons. 
 
 Apart from chemokines, Spp1 and SerpinA3N were also highly up-
regulated. Both of these can be expressed in the brain at low levels under 
normal conditions, but are mostly secreted in the PNS. They have been 
observed to be involved in inflammation (Pelissier et al. 2008, Braitch & 
Constantinescu 2010). SerpinA3N in particular has been associated with 
AD, where elevated levels were found in senile plaques (Padmanabhan et 
al. 2006). At later time points after KA injection, Spp1 remained highly up-
regulated. In addition, upregulation of Cd74 and several RT1 (rat) genes 
were also observed. These are encoded by MHC found predominantly on 
the surface of B lymphocytes and antigen-presenting cells (Eccles et al. 
1986) and mediate leukocytes. Increased expression of Cd74 was 
observed in neurons and microglia in AD (Bryan et al. 2008). Increased 
expression of RT1 genes may also represent a defensive response in the 
CNS, which are otherwise at low levels in normal conditions.  
 





Further elevated levels of these molecules after KA injury could 
suggest infiltration from the PNS into the brain. In brain injury, the BBB 
increases in permeability and may break down, allowing access of small  
molecules across, where neurotoxins are released, thereby activating a 
cascade of inflammatory events or activation of macrophages (Raivich et 
al. 1999, del Zoppo et al. 2000). Blood-brain barrier disruption and brain 
infiltration of macrophage and T-cells have previously been observed in 
the KA-lesioned hippocampus (Zattoni et al. 2011). Studies have shown 
that the expression of Ccl2 and MIP-2 also alters BBB permeability and 
recruits different leukocytes to the site of injury, aggravating the local 
inflammatory response ( Biber et al. 2002, Kalehua et al. 2004). Ccl2 is a 
mediator of excitotoxic injury in vivo as well as a potent chemoattractant 
for monocytes and macrophages. Monocytes were observed in ICAM-1-
positive vessels in the hippocampal fissure, around the injection site and in 
the meninges after intracranial injection of Ccl2. α-chemokines MIP-2 and 
IL-8 were also shown to cause more PMN recruitment to the brain 
parenchyma following CNS injury (Bell et al. 1996).  
 
Infiltration of the CNS involves several cell adhesion steps such as 
P-selectin and E-selectin, both of which were highly up-regulated in 1 day 
after KA injection, to provide signals for leukocytes into the brain. The role 
of P- and E-selectin reduces the rate of leukocytes in the blood stream by 
binding to L-selectin, which is strengthened under the release of 
chemokines from the site of injury (Stoll et al. 2002). 





 The temporal events that occur after KA injury give an idea of the 
various stages of inflammation and the respective genes associated at 
each stage. From early inflammation, the upregulation of chemokines and 
other genes was most notable; however, towards the later stages of 
inflammation, these mediators are moderated and are overtaken by RT1 
genes. The findings from the present study are generally similar to results 
from previous animal and human studies which identified specific genes in 
neuronal injury (Manley et al. 2007, van Gassen et al. 2008, Sharma et al. 
2009, Worthmann et al. 2010). The similarities in changes in expression of 
genes in the present study on an animal model and clinical studies help to 
confirm the pattern of brain gene expression changes after excitotoxic 
brain injury. 
 
The second part of the present study gave an insight on how 
targeting a pro-inflammatory chemokine with an antagonist can help 
ameliorate inflammation and prevent further neuronal cell death. Few 
studies, with the exception of MS, a progressive autoimmune disease of 
the CNS characterized by inflammatory lesions in the brain, have 
demonstrated the effects of Ccr2 antagonist against injury or inflammation 
in the brain. In a study of focal cerebral ischemia in mice, Ccr2 antagonist, 
TAK-779, was observed to decrease the infarct volume in mice with middle 
cerebral artery occlusion, suggesting that Ccr2 antagonist may be 
protective against cerebral ischemia (Takami et al. 2002). Although in 
clinical trials, successful results for Ccr2 antagonist have yet to be seen, it 




is hoped that the positive findings from this experiment can lend further 
support for the development of better antagonists.  
 
 More work can be done to further expand on the present study - 
detailed study of the genes up-regulated in the CNS and comparing them 
to the levels in the PNS may possibly provide important clues to the way 
each gene functions under physiological conditions. Time points in the 
present study can also be increased to examine more closely each stage 
of inflammation and to examine the morphological changes at each time 
point. Narrowing down the study to individual gene of interest may also 
lend focus to the way each gene functions in the CNS under injury. In the 
antagonist study, no in vivo study has used RS-504393 in therapeutic 
treatment of rats before, therefore the appropriate dosage of drug for rats 
needs to be determined before significant changes can be observed in the 
levels of Ccl2. Ultimately the challenge is to determine common and 
distinct underlying mechanisms that can eventually help identify both 
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